WO2014078963A1 - Anti-lg3 antibody inhibition in the prevention and/or treatment of vascular rejection and related diseases and conditions - Google Patents
Anti-lg3 antibody inhibition in the prevention and/or treatment of vascular rejection and related diseases and conditions Download PDFInfo
- Publication number
- WO2014078963A1 WO2014078963A1 PCT/CA2013/050891 CA2013050891W WO2014078963A1 WO 2014078963 A1 WO2014078963 A1 WO 2014078963A1 CA 2013050891 W CA2013050891 W CA 2013050891W WO 2014078963 A1 WO2014078963 A1 WO 2014078963A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antibodies
- transplant recipient
- ligand
- remodeling
- antibody
- Prior art date
Links
- 230000002792 vascular Effects 0.000 title claims description 30
- 238000011282 treatment Methods 0.000 title description 15
- 230000002265 prevention Effects 0.000 title description 4
- 201000010099 disease Diseases 0.000 title description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title description 3
- 230000005764 inhibitory process Effects 0.000 title description 2
- 238000000034 method Methods 0.000 claims abstract description 109
- 239000007787 solid Substances 0.000 claims abstract description 62
- 210000000056 organ Anatomy 0.000 claims abstract description 42
- 230000003247 decreasing effect Effects 0.000 claims abstract description 38
- 208000035868 Vascular inflammations Diseases 0.000 claims abstract description 32
- 230000000735 allogeneic effect Effects 0.000 claims abstract description 32
- 238000007634 remodeling Methods 0.000 claims abstract description 29
- 230000003472 neutralizing effect Effects 0.000 claims abstract description 8
- 230000001640 apoptogenic effect Effects 0.000 claims description 89
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 45
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 41
- 229920001184 polypeptide Polymers 0.000 claims description 40
- 238000002054 transplantation Methods 0.000 claims description 36
- 239000003446 ligand Substances 0.000 claims description 34
- 230000001154 acute effect Effects 0.000 claims description 29
- 239000000523 sample Substances 0.000 claims description 21
- 239000012472 biological sample Substances 0.000 claims description 20
- 239000003795 chemical substances by application Substances 0.000 claims description 19
- 210000002889 endothelial cell Anatomy 0.000 claims description 12
- 238000002616 plasmapheresis Methods 0.000 claims description 11
- 238000004587 chromatography analysis Methods 0.000 claims description 10
- 239000012539 chromatography resin Substances 0.000 claims description 8
- 239000012504 chromatography matrix Substances 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 7
- 230000003993 interaction Effects 0.000 claims description 7
- 210000003734 kidney Anatomy 0.000 claims description 7
- 238000002617 apheresis Methods 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 4
- 241000699670 Mus sp. Species 0.000 description 35
- 210000004369 blood Anatomy 0.000 description 25
- 239000008280 blood Substances 0.000 description 25
- 210000004027 cell Anatomy 0.000 description 17
- 230000000302 ischemic effect Effects 0.000 description 17
- 208000034827 Neointima Diseases 0.000 description 15
- 210000004379 membrane Anatomy 0.000 description 14
- 239000012528 membrane Substances 0.000 description 14
- 230000008692 neointimal formation Effects 0.000 description 14
- 102000004169 proteins and genes Human genes 0.000 description 14
- 108090000623 proteins and genes Proteins 0.000 description 14
- 238000002347 injection Methods 0.000 description 13
- 239000007924 injection Substances 0.000 description 13
- 208000028867 ischemia Diseases 0.000 description 13
- 238000001356 surgical procedure Methods 0.000 description 13
- 230000003966 vascular damage Effects 0.000 description 12
- 230000008021 deposition Effects 0.000 description 11
- 241001529936 Murinae Species 0.000 description 10
- 239000000427 antigen Substances 0.000 description 10
- 108091007433 antigens Proteins 0.000 description 10
- 102000036639 antigens Human genes 0.000 description 10
- 210000000709 aorta Anatomy 0.000 description 10
- 239000011159 matrix material Substances 0.000 description 10
- 230000003511 endothelial effect Effects 0.000 description 9
- 230000008595 infiltration Effects 0.000 description 9
- 238000001764 infiltration Methods 0.000 description 9
- 210000000822 natural killer cell Anatomy 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 9
- 238000010186 staining Methods 0.000 description 9
- 241000282414 Homo sapiens Species 0.000 description 8
- 210000001744 T-lymphocyte Anatomy 0.000 description 8
- 208000024248 Vascular System injury Diseases 0.000 description 8
- 208000012339 Vascular injury Diseases 0.000 description 8
- 230000008901 benefit Effects 0.000 description 8
- 238000001514 detection method Methods 0.000 description 8
- 230000006378 damage Effects 0.000 description 7
- 230000004054 inflammatory process Effects 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 102100036597 Basement membrane-specific heparan sulfate proteoglycan core protein Human genes 0.000 description 6
- 102000003952 Caspase 3 Human genes 0.000 description 6
- 108090000397 Caspase 3 Proteins 0.000 description 6
- 125000003275 alpha amino acid group Chemical group 0.000 description 6
- 238000003364 immunohistochemistry Methods 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 238000000926 separation method Methods 0.000 description 6
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 5
- 206010052779 Transplant rejections Diseases 0.000 description 5
- 206010003230 arteritis Diseases 0.000 description 5
- 239000003636 conditioned culture medium Substances 0.000 description 5
- 210000000265 leukocyte Anatomy 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- 238000010172 mouse model Methods 0.000 description 5
- 230000001717 pathogenic effect Effects 0.000 description 5
- 108010049224 perlecan Proteins 0.000 description 5
- 229920005989 resin Polymers 0.000 description 5
- 229940122739 Calcineurin inhibitor Drugs 0.000 description 4
- 101710192106 Calcineurin-binding protein cabin-1 Proteins 0.000 description 4
- 102100024123 Calcineurin-binding protein cabin-1 Human genes 0.000 description 4
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 4
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 4
- 239000011324 bead Substances 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 230000003053 immunization Effects 0.000 description 4
- 239000003018 immunosuppressive agent Substances 0.000 description 4
- 229940125721 immunosuppressive agent Drugs 0.000 description 4
- 210000002540 macrophage Anatomy 0.000 description 4
- 210000005087 mononuclear cell Anatomy 0.000 description 4
- RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- 239000012679 serum free medium Substances 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 238000011725 BALB/c mouse Methods 0.000 description 3
- 208000032594 Vascular Remodeling Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 238000001042 affinity chromatography Methods 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 230000027455 binding Effects 0.000 description 3
- 210000000601 blood cell Anatomy 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 230000030833 cell death Effects 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 210000001808 exosome Anatomy 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- WZUVPPKBWHMQCE-XJKSGUPXSA-N (+)-haematoxylin Chemical compound C12=CC(O)=C(O)C=C2C[C@]2(O)[C@H]1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-XJKSGUPXSA-N 0.000 description 2
- HSTOKWSFWGCZMH-UHFFFAOYSA-N 3,3'-diaminobenzidine Chemical compound C1=C(N)C(N)=CC=C1C1=CC=C(N)C(N)=C1 HSTOKWSFWGCZMH-UHFFFAOYSA-N 0.000 description 2
- YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 description 2
- VHRSUDSXCMQTMA-PJHHCJLFSA-N 6alpha-methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 description 2
- 206010068406 Capillaritis Diseases 0.000 description 2
- 229930105110 Cyclosporin A Natural products 0.000 description 2
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 2
- 108010036949 Cyclosporine Proteins 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 108010026552 Proteome Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000003872 anastomosis Effects 0.000 description 2
- 230000001028 anti-proliverative effect Effects 0.000 description 2
- 210000000702 aorta abdominal Anatomy 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 2
- 229960002170 azathioprine Drugs 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 239000012876 carrier material Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 230000001143 conditioned effect Effects 0.000 description 2
- 239000003246 corticosteroid Substances 0.000 description 2
- 229960001334 corticosteroids Drugs 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000016784 immunoglobulin production Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 229960004584 methylprednisolone Drugs 0.000 description 2
- 229960004866 mycophenolate mofetil Drugs 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 230000000861 pro-apoptotic effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000007320 rich medium Substances 0.000 description 2
- 229960002930 sirolimus Drugs 0.000 description 2
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 238000002798 spectrophotometry method Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 229960001967 tacrolimus Drugs 0.000 description 2
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- 208000003918 Acute Kidney Tubular Necrosis Diseases 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 108050008874 Annexin Proteins 0.000 description 1
- 102000000412 Annexin Human genes 0.000 description 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 101100454807 Caenorhabditis elegans lgg-1 gene Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 101150100916 Casp3 gene Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 102000000989 Complement System Proteins Human genes 0.000 description 1
- 108010069112 Complement System Proteins Proteins 0.000 description 1
- JJLJMEJHUUYSSY-UHFFFAOYSA-L Copper hydroxide Chemical compound [OH-].[OH-].[Cu+2] JJLJMEJHUUYSSY-UHFFFAOYSA-L 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 208000002087 Endarteritis Diseases 0.000 description 1
- 101800001739 Endorepellin Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 108010040476 FITC-annexin A5 Proteins 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 238000000729 Fisher's exact test Methods 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
- 101001000001 Homo sapiens Basement membrane-specific heparan sulfate proteoglycan core protein Proteins 0.000 description 1
- 101000582320 Homo sapiens Neurogenic differentiation factor 6 Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- 101800000911 LG3 peptide Proteins 0.000 description 1
- 102400001100 LG3 peptide Human genes 0.000 description 1
- 238000000585 Mann–Whitney U test Methods 0.000 description 1
- 102100030589 Neurogenic differentiation factor 6 Human genes 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010038540 Renal tubular necrosis Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 108700012920 TNF Proteins 0.000 description 1
- 206010060872 Transplant failure Diseases 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 230000005735 apoptotic response Effects 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000007640 basal medium Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 238000012754 cardiac puncture Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 230000024203 complement activation Effects 0.000 description 1
- 238000000942 confocal micrograph Methods 0.000 description 1
- 238000004624 confocal microscopy Methods 0.000 description 1
- 238000010924 continuous production Methods 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 239000005289 controlled pore glass Substances 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000012137 double-staining Methods 0.000 description 1
- 238000000635 electron micrograph Methods 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 210000004954 endothelial membrane Anatomy 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 239000000446 fuel Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- 230000000322 hemodialysis Effects 0.000 description 1
- 230000002962 histologic effect Effects 0.000 description 1
- 239000012510 hollow fiber Substances 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000005934 immune activation Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 230000002530 ischemic preconditioning effect Effects 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 238000009115 maintenance therapy Methods 0.000 description 1
- 238000011177 media preparation Methods 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 238000002406 microsurgery Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000002487 multivesicular body Anatomy 0.000 description 1
- VELGMVLNORPMAO-JTFNWEOFSA-N n-[(e)-1-[(3r,4r,5s,6r)-5-[(2s,3r,4r,5r,6r)-5-[(2s,3r,4r,5r,6r)-3-acetamido-5-hydroxy-6-(hydroxymethyl)-4-[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,4-dihydroxy-6-(hydroxym Chemical compound O[C@@H]1[C@@H](O)C(OCC(NC(=O)CCCCCCCCCCCCCCCCC)C(O)\C=C\CCCCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)[C@@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](CO)O1 VELGMVLNORPMAO-JTFNWEOFSA-N 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002540 product ion scan Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 210000002254 renal artery Anatomy 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000822 sequential centrifugation Methods 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 238000004885 tandem mass spectrometry Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 210000003606 umbilical vein Anatomy 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4725—Proteoglycans, e.g. aggreccan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/44—Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
Definitions
- the present invention generally relates to vascular damage and transplant rejection, and more specifically to the prevention and/or of vascular damage and/or acute vascular rejection and related diseases and conditions.
- MHC major histocompatibility complex
- HLA human leukocyte antigen
- Acute rejection usually occurs within the first weeks after transplantation. It is typically caused by mismatched HLA antigens that are present on all cells, which leads to activation of T cells in the host (or transplant recipient). HLA antigens are polymorphic therefore the chance of a perfect match is extremely rare. Endothelial cells in vascularized grafts such as kidneys are typically the earliest victims of acute rejection. Damage to the endothelial lining is often an early predictor of irreversible acute graft failure. The risk of acute rejection is highest in the first 3 months after transplantation, and is lowered by immunosuppressive agents in maintenance therapy.
- HLA non-human leukocyte antigen
- Immunosuppressive agents currently used to prevent or treat acute rejection of solid- organ transplant such as calcineurin inhibitor (CNI) drugs (e.g., cyclosporine A, tacrolimus), corticosteroids (e.g., methylprednisolone), anti-proliferative agents (e.g., mycophenolate mofetil or MMF, azathioprine), and mammalian-target-of-rapamycin (mTOR) inhibitors (e.g., sirolimus), generally exhibit poor specificity and thus are associated with several and significant side effects.
- CNI calcineurin inhibitor
- mTOR mammalian-target-of-rapamycin
- the present invention relates to the following items 1 to 37:
- a method for preventing or decreasing vascular inflammation and/or obliterative remodeling in an allogeneic solid organ transplant recipient comprising decreasing the level of, or neutralizing, anti-LG3 antibodies in the transplant recipient.
- treating comprises contacting the biological sample comprising anti-LG3 antibodies from the transplant recipient with a ligand that binds to the anti-LG3 antibodies, and removing the anti-LG3 antibody-ligand complexes from the biological sample.
- the ligand is an LG3 polypeptide.
- the LG3 polypeptide comprises the sequence of SEQ ID NO:2 (FIG. 2C), or a sequence having at least 60% similarity or identity with the sequence of SEQ ID NO:2 (FIG. 2C).
- LG3 polypeptide comprises the sequence of SEQ ID NO:2 (FIG. 2C), or a sequence having at least 80% similarity or identity with the sequence of SEQ ID NO:2 (FIG. 2C).
- LG3 polypeptide comprises the sequence of SEQ ID NO:2 (FIG. 2C).
- kits for preventing or decreasing vascular inflammation and/or obliterative remodeling in an allogeneic solid organ transplant recipient comprising a ligand that binds to anti-LG3 antibodies bound to a solid support.
- kit of item 30 wherein the solid support is a chromatography resin or matrix.
- kit of item 30 or 31 wherein the kit further comprises a chromatography column.
- kit of any one of items 30 to 32 for preventing or decreasing vascular inflammation and/or obliterative remodeling in an allogeneic solid organ transplant recipient.
- An apheresis or plasmapheresis device comprising a chromatography column, the column comprising a ligand that binds to anti-LG3 antibodies bound to a solid support.
- FIG. 1A shows the structure of perlecan
- FIG. 1 B shows the structure of Domain V/Endorepellin of perlecan, with the C-terminal LG3 domain circled;
- FIGs. 2A and 2B show the amino acid sequence of human basement membrane-specific heparan sulfate proteoglycan core protein precursor (also known as perlecan, NCBI reference sequence No. NP_005520, SEQ ID NO:1), with the putative amino acids forming the LG3 domain (spanning about residues 4201-4389) depicted in bold;
- FIG. 2C show the putative amino acid sequence of human LG3 (SEQ ID NO:2)
- H&E Hematoxylin and eosin
- Anti-donor antibodies are expressed in arbitrary unit (AU).
- (D) Anti-donor IgG titers in mice that received an allograft exposed to warm ischemia for 15 min assessed pretransplantation (pre), 10 days and 3 weeks post-surgery (n 8 for each time point).
- FIG. 4 shows H&E stained section of adjacent isogenic aorta to an allograft exposed to warm ischemia for 30 min pre-transplantation and harvested 3 weeks post-surgery (magnification: 20X);
- (C) Intima/media ratio in mice transplanted with a non-ischemic allograft, passively transferred with control IgG or anti-LG3 IgG and sacrificed 3 weeks post-surgery (n 6 for each group).
- (D) H&E-stained aortic allografts from mice transplanted with a non-ischemic allograft and passively transferred with control IgG or anti-LG3 IgG (n 6 per group) and sacrificed 3 weeks post-surgery.
- the square insert indicates the magnified area (Lower panels, magnification: 40X).
- the arrow indicates neointima formation;
- FIG. 6 shows murine IgG subclasses levels (expressed as optical density X1 ,000) in anti-LG3 IgG used for passive transfer.
- FIG. 8 shows H/E staining and immunohistochemistry for C4d deposition in adjacent isogenic aorta sections in allografted mice passively transferred with control IgG or anti-LG3 IgG;
- FIG. 10A shows that LG3 is released by apoptotic EC through caspase-3-dependent pathways.
- FIG. 10B shows electron micrographs of purified apoptotic nanovesicles and apoptotic bodies from apoptotic HUVEC. Note the difference in scale demonstrating size differences. Nanovesicles present a typical cup-shape morphology;
- FIG. 10C shows that LG3 was identified within both apoptotic bodies and apoptotic nanovesicles produced by serum starved apoptotic EC by unbiased proteomic screen where the proteomes of endothelial apoptotic bodies and apoptotic nanovesicles were compared (in collaboration with Dr. Pierre Thibault, Universite de Montreal). Briefly, 12 ug of proteins from apoptotic bodies and nanovesicles were separated by SDS-PAGE and digested by trypsin. Peptides were extracted and separated on a nano-LC column coupled to an LTQ-OrbitrapTM mass spectrometer followed by three product ion scans (MS/MS). The table shows the different LG3 peptides identified.
- FIG. 10D shows a confocal microscopy image confirming the presence of LG3 within membrane vesicles released by apoptotic EC.
- FIGs. 11A and 11 B show that in a murine model of vascular rejection, injections of nanovesicles from recipient endothelial apoptotic cells increase anti-LG3 antibody production and early neointima formation. In contrast, injections of apoptotic bodies alone or of combined apoptotic bodies and apoptotic nanovesicles did not increase anti-LG3 titers nor neointima formation.
- FIG. 11 A Anti-LG3 titers in sera collected 3 weeks post-surgery from mice injected i.v.
- mice receiving an allogeneic aortic graft exposed to ischemia prior to transplantation and in which anti-LG3 antibodies were passively transferred showed evidence of early neointima formation and increased infiltration of the allograft by mononuclear cells 3 weeks after transplantation.
- the present invention provides a method for preventing or decreasing vascular inflammation and/or obliterative remodeling in an allogeneic solid organ transplant recipient, said method comprising decreasing the level of, or neutralizing, anti-LG3 antibodies in said transplant recipient.
- Vascular inflammation following allogeneic solid organ transplant recipient may be measured, for example, by detection mononuclear cell (e.g., T cells, NK cells) infiltration, deposition of complement fragments (e.g., C4d, C1 q), and/or increased cytokine/chemokine secretion.
- Obliterative remodeling may be determined, for example, by detecting neointima formation (e.g., increased intima-media ratios).
- Vascular inflammation and/or obliterative remodeling typically occur, for example, during vascular rejection.
- the above-mentioned method prevents or decreases vascular rejection, in a further embodiment acute or subacute vascular rejection, in the transplant recipient.
- the above-mentioned method prevents or decreases acute vascular rejection in the transplant recipient.
- the above-mentioned method comprises (selectively or nonselective ⁇ ) decreasing the level of said anti-LG3 antibodies in said transplant recipient.
- the method comprises treating a biological sample that comprises anti-LG3 antibodies from the transplant recipient to remove the anti-LG3 antibodies (i.e. decreasing the level/amount thereof), and reintroducing the treated biological sample (that contain no or less anti-LG3 antibodies) into the transplant recipient.
- "Selectively" decreasing the level of anti-LG3 antibodies means that the level of anti-LG3 antibodies is decreased preferentially relative to other antibodies (either in absolute and/or relative amounts).
- the above-mentioned biological sample is a biological fluid, e.g. , lymph, or a blood-derived sample.
- blood-derived sample refers to blood (e.g. , fresh blood, stored blood) or to a fraction thereof, such as serum, plasma and the like. It also refers to any sample that may be obtained following one or more purification, enrichment, and/or treatment steps using blood (obtained by venous puncture, for example) as starting material.
- the above-mentioned blood-derived sample is blood or plasma.
- the method comprises collecting a biological sample (e.g., blood) from the subject, treating the sample to remove the anti-LG3 antibodies (i.e. decreasing the level/amount thereof), and reintroducing the treated biological sample.
- a biological sample e.g., blood
- the treatment comprises contacting the biological sample comprising anti-LG3 antibodies with a ligand that binds to said anti-LG3 antibodies, removing the anti-LG3 antibodies-ligand complexes from the biological sample, and reintroducing the treated biological sample (that contain no or less anti-LG3 antibodies) into the transplant recipient (immunoadsorption).
- the above-mentioned ligand is an antibody.
- the antibody non-specifically recognizes anti-LG3 antibodies, i.e. binds to all antibodies present in the sample.
- the antibody is an anti-lgG antibody, in a further embodiment an anti-human IgG antibody.
- the antibody specifically recognizes anti-LG3 antibodies, i.e. binds preferentially to anti-LG3 antibodies relative to other antibodies present in the sample.
- a specific antibody may be generated by immunizing an animal with one or more of the complement determining regions (CDR1 , CDR2 and/or CDR3) of anti-LG3 antibodies. Methods to generate antibodies against an antigen are well known in the art.
- the ligand is an LG3 polypeptide.
- LG3 polypeptide refers to a polypeptide comprising a sequence corresponding to an LG3 polypeptide (an LG3 polypeptide domain), in a further embodiment a human LG3 polypeptide/protein.
- LG3 polypeptide/protein refers to a C-terminal domain of the perlecan polypeptide (FIGs. 1 B and 2A-2B, SEQ ID NO: 1), in an embodiment a domain comprising an amino acid sequence corresponding to about residues 4197 to about residue 4391 of the amino acid sequence of FIGs. 2A and 2B (SEQ ID NO: 1), for example from about residue 4201 to about residue 4389 (FIG.
- the ligand may be the entire perlecan polypeptide, or any fragment or variant thereof that comprises the sequence of the LG3 region, or a sequence having at least 60, 65, 70, 75, 80, 85, 90, or 95% similarity or identity with the sequence of the LG3 region, and that retains the ability to bind to anti-LG3 antibodies present in a transplant recipient.
- Sequence identity refers to the degree of correspondence between two sequences, or the fraction of amino acids that are the same between two aligned sequences.
- Sequence similarity refers to the degree of resemblance between two sequences when they are compared, which is be calculated using a suitable similarity matrix, such as the PAM matrix or the BLOSUM matrix. Percent similarity and identity may be determined, for example, using well known algorithms and software. Optimal alignment of sequences for comparisons of identity/similarity may be conducted using a variety of algorithms, such as the local homology algorithm of Smith and Waterman, 1981 , Adv. Appl. Math 2: 482, the homology alignment algorithm of Needleman and Wunsch, 1970, J. Mol. Biol. 48: 443, the search for similarity method of Pearson and Lipman, 1988, Proc. Natl. Acad. Sci.
- the ligand is an LG3 polypeptide/protein fragment.
- LG3 polypeptide/protein fragment refers to a portion of the LG3 polypeptide/protein defined above and that is capable of binding to anti-LG3 antibodies present in biological samples from subjects, e.g. , a portion of the LG3 polypeptide/protein preferentially targeted by the anti-LG3 antibodies.
- the LG3 polypeptide comprises the sequence of SEQ ID NO:2 (FIG. 2C), or a sequence having at least 60, 65, 70, 75, 80, 85, 90, 91 , 92, 93, 94, 95, 96, 97, 98 OR 99% similarity or identity with the sequence of SEQ ID NO:2 (FIG. 2C), and retains the ability to bind to anti-LG3 antibodies present in a transplant recipient.
- the LG3 polypeptide comprises the sequence of SEQ ID NO:2 (FIG. 2C), or comprises a sequence having at least 60% similarity or identity with the sequence of SEQ ID NO:2 (FIG. 2C).
- the LG3 polypeptide comprises the sequence of SEQ ID NO:2 (FIG. 2C), or comprises a sequence having at least 80% similarity or identity with the sequence of SEQ ID NO:2 (FIG. 2C). In another embodiment, the LG3 polypeptide comprises the sequence of SEQ ID NO:2 (FIG. 2C). In embodiments, the LG3 polypeptide may comprise, further to the LG3 polypeptide domain defined above, one more amino acids covalently linked to the amino- and/or carboxy-termini of said LG3 polypeptide domain.
- the above-mentioned LG3 polypeptide may thus be a chimeric or fusion peptide containing an LG3 polypeptide domain as described herein, linked at its amino- or carboxy-terminal end, or both, to an amino acid sequence of a different protein or peptide.
- the above-mentioned LG3 polypeptide may comprise a peptide moiety, for example for facilitating its purification, detection and/or attachment to a solid support (a "tag", such as a "His-tag” or a GST-tag”).
- the above-mentioned LG3 polypeptide may comprise any other chemical moiety, which may be useful for example to stabilize, detect and/or purify the LG3 polypeptide.
- the LG3 polypeptide consists of the sequence of SEQ ID NO:2 (FIG. 2C).
- the ligand (e.g., LG3 polypeptide) is bound (covalently or non- covalently) to a solid support.
- the ligand is covalently bound to, or immobilized on, a solid support.
- the ligand (e.g., LG3 polypeptide) may be immobilized to the solid support via a specific binding agent like a chemical group or a peptide group without significantly affecting the specific binding affinity.
- the above-mentioned solid support is a chromatography matrix/resin.
- the chromatography matrix/resin used according to the invention can be any material known in the art which is suitable for affinity separation, such as for example porous carrier materials, specifically porous solid phase carrier materials. Any conventional carrier material may be used, but is not limited to, agarose, SepharoseTM, polysterene, controlled pore glass, dextrans, cellulose, synthetic polymers and copolymers like hydrophilic polymers, porous amorphous silica.
- the chromatography matrix/resin may be particulate like beads or granules generally used in columns or in sheet form like membranes or filters which may be flat, pleated, hollow fibers or tubes.
- the above-mentioned matrix/resin is provided in the form of a column (chromatography column), e.g. , wherein the matrix is packed in a column.
- the beads may be provided in various sizes, depending, in part, on the nature of the sample being applied, where suitable bead sizes include from about 10 ⁇ to about 500 ⁇ , e.g. , from about 10 ⁇ to about 200 ⁇ , from about 20 ⁇ to about 150 ⁇ , from about 50 ⁇ to about 150 ⁇ .
- suitable bead sizes include from about 10 ⁇ to about 500 ⁇ , e.g. , from about 10 ⁇ to about 200 ⁇ , from about 20 ⁇ to about 150 ⁇ , from about 50 ⁇ to about 150 ⁇ .
- suitable bead sizes include from about 10 ⁇ to about 500 ⁇ , e.g. , from about 10 ⁇ to about 200 ⁇ , from about 20 ⁇ to about 150 ⁇ , from about 50 ⁇ to about 150 ⁇ .
- binding to the matrix may for example be achieved by column chromatography, batch treatment, or expanded bed absorption approaches.
- Column chromatography typically entails packing the solid matrix onto a chromatography column and passing the sample through the column to allow binding of the antibodies, the flow through being free or substantially free of antibodies, more particularly anti-LG3 antibodies.
- Batch treatment typically entails combining the sample (e.g., plasma) with the solid matrix in a vessel, mixing, separating the solid matrix (which contains the ligand/anti-LG3 complexes), and collecting the liquid phase that is free or substantially free of antibodies, more particularly anti- LG3 antibodies.
- the above-mentioned methods are performed in vivo or in vitro, in a further embodiment in vitro.
- the above-mentioned method is performed through/during (extracorporeal) anapheresis or plasmapheresis.
- Apheresis is a method wherein the therapeutic effects are based on the extracorporeal elimination of pathogenic proteins, protein-bound pathogenic substances, free pathogenic substances or pathogenic cells of the blood, in case of the present invention it is the removal of anti-LG3 antibodies.
- the pathogenic protein can only be eliminated from cell-free plasma, plasma previously is separated from the blood cells by means of a membrane plasma separator (plasma separation) or by means of a haemocentrifuge.
- plasma separation membrane plasma separator
- haemocentrifuge a haemocentrifuge.
- the anti-LG3 antibodies are specifically adsorbed directly from the non-pretreated blood without a previous plasma separation, whereby, in contrast to the plasma separation methods, both the plasma separation and the addition of a substitution solution can be omitted.
- Plasmapheresis blood is initially taken out of the body through a needle or previously implanted catheter. Plasma is then removed from the blood by a cell separator. Three procedures are commonly used to separate the plasma from the blood:
- Discontinuous flow centrifugation One venous catheter line is used. Typically, a 300 ml batch of blood is removed at a time and centrifuged to separate plasma from blood cells.
- Continuous flow centrifugation Two venous lines are used. This method requires slightly less blood volume to be out of the body at any one time as it is able to continuously spin out plasma.
- Plasma filtration Two venous lines are used. The plasma is filtered using standard hemodialysis equipment. This continuous process requires less than 100 ml of blood to be outside the body at one time.
- the blood of a patient is cleared from immunoglobulin (e.g., anti-LG3 antibodies) by an extracorporeal affinity purification step, chromatography column.
- immunoglobulin e.g., anti-LG3 antibodies
- the blood cells are returned to the person undergoing treatment, while the plasma, which contains the antibodies, is first treated and then returned to the patient in traditional plasmapheresis.
- Medication to keep the blood from clotting e.g., an anticoagulant is generally given to the patient during the procedure.
- the above-mentioned method comprises: (a) obtaining a sample of blood from the transplant recipient; (b) isolating the plasma from the cellular components from said blood sample; (c) contacting said isolated plasma with a ligand that binds to the anti-LG3 antibodies as described above, whereby anti-LG3 antibodies are retained by the ligand (e.g. bound to a solid support such as a chromatography resin); (d) reintroducing the cellular components isolated from step (b) and the purified plasma from step (c) to the patient, e) and optionally repeating the steps c) and d) at least once.
- at least 50%, 60%, 70%, 80%, 85%, 90% or 95% of the anti-LG3 antibodies are removed from the biological sample (e.g., plasma).
- the above-mentioned method comprises administering an effective amount of apoptotic bodies, such as autologous apoptotic bodies, to the transplant recipient.
- apoptotic bodies are derived from endothelial cells.
- Apoptotic bodies also called apobodies
- the formation of apoptotic bodies is a mechanism preventing leakage of potentially toxic or immunogenic cellular contents of dying cells and prevents inflammation or autoimmune reactions as well as tissue destruction.
- apoptotic bodies or apoptotic bodies-rich medium are well known in art (see, e.g., Example 1 below).
- isolated confluent human umbilical vein endothelial cells (HUVECs) may be incubated for a certain period of time (e.g., 12-36 hours, 24 hours) in endothelial basal medium without serum and growth factors to induce apoptosis (in the presence or not of TNFa).
- Apoptosis may be monitored/characterized by double staining with annexin V-fluorescein isothiocyanate (FITC) and propidium iodide (PI).
- FITC annexin V-fluorescein isothiocyanate
- PI propidium iodide
- HUVEC-derived apoptotic bodies-rich medium ABRM
- Apoptotic bodies may be characterized by flow cytometry after staining with annexin V-FITC and PI.
- the method comprises neutralizing the anti-LG3 antibodies in the transplant recipient.
- the method comprises administering to the transplant recipient an effective amount of an agent that binds to anti-LG3 antibodies and inhibits their interaction with LG3.
- an agent that binds to anti-LG3 antibodies and inhibits their interaction with LG3 could foster intragraft expression of LG3 which in turn facilitates anti-LG3 antibody deposition, fuels further anti-LG3 antibody production, and enhances immune activation/inflammation at sites of allograft damages. Therefore, any agent that binds to anti- LG3 antibodies and inhibits their interaction with LG3, thus inhibiting anti-LG3 antibody deposition, would be suitable for preventing or decreasing vascular inflammation and/or obliterative remodeling in an allogeneic solid organ transplant recipient.
- the agent is an antibody, for example an antibody that binds to anti-LG3 antibodies and inhibits their interaction with LG3.
- a specific antibody may be generated by immunizing an animal with one or more of the complement determining regions (CDR1 , CDR2 and/or CDR3) of anti-LG3 antibodies. Methods to generate antibodies against an antigen are well known in the art.
- the agent is an LG3 polypeptide fused to a targeting moiety, to tether/attract the anti-LG3 antibodies away from the sites of allograft damages.
- the targeting moiety could target the LG3 polypeptide/anti-LG3 antibodies complexes to another organ or tissue (remote from the allograft), in which there is no inflammation.
- the transplant may be from a living donor or a deceased donor (cadaveric).
- cadaveric cadaveric
- anti-LG3 antibodies appear to be more particularly detrimental in an ischemic microenvironment, which is typically sustained by organs from deceased donors (i.e. typically to a greater extent as compared to organs from living donors). Accordingly, in an embodiment, the transplant is from a deceased donor.
- the above-mentioned method may be performed prior to and/or after the transplantation. In a further embodiment, the above-mentioned method is performed prior to the transplantation, so as to eliminate, or decrease the level of, anti-LG3 antibodies in the candidate transplant recipient prior to transplantation.
- the present invention provides a method for preventing or decreasing vascular inflammation and/or obliterative remodeling in a candidate allogeneic solid organ transplant recipient, said method comprising decreasing the level of, or neutralizing, anti-LG3 antibodies in said candidate transplant recipient (prior to transplantation).
- the above-mentioned method further comprises measuring or determining the levels of anti-LG3 antibodies in the transplant recipient (e.g., candidate transplant recipient). In another embodiment, the method further comprises selecting a transplant recipient (e.g., candidate transplant recipient) having elevated or increased levels of anti-LG3 antibodies, relative to a control level.
- a transplant recipient e.g., candidate transplant recipient
- the values for anti-LG3 levels can be absolute or relative values, e.g. , values provided in comparison to control levels.
- the values for expression levels can be raw values, or values that are optionally rescaled, filtered and/or normalized. The approach used will depend, for example, on the intended use for the data.
- the values for anti-LG3 levels may correspond to the intensity of a signal measured using a suitable device (e.g. , optical density (OD) values at a given wavelength measured using a spectrometer), or to an estimated anti-LG3 levels (based on a standard curve established using known concentrations of anti-LG3, for example).
- Control level or “reference level” or “standard level” are used interchangeably herein and broadly refers to a separate baseline level measured in a comparable control sample, which is generally from a subject not suffering from vascular damage or acute vascular rejection or not at risk of suffering from vascular damage or acute vascular rejection.
- the corresponding control level may be a level corresponding to an average/mean or median level calculated based of the levels measured in several reference or control subjects (e.g. , a pre-determined or established standard level).
- the control level may be a pre-determined "cut-off value recognized in the art or established based on levels measured in one or a group of control subjects.
- the corresponding reference/control level may be adjusted or normalized for age, gender, race, or other parameters.
- control level can thus be a single number/value, equally applicable to every patient individually, or the control level can vary, according to specific subpopulations of patients. Thus, for example, older men might have a different control level than younger men, and women might have a different control level than men.
- the predetermined standard level can be arranged, for example, where a tested population is divided equally (or unequally) into groups, such as a low-risk group, a medium-risk group and a high-risk group or into quadrants or quintiles, the lowest quadrant or quintile being individuals with the lowest amount of anti-LG3 antibodies (who are less likely to benefit from the treatment) and the highest quadrant or quintile being individuals with the highest amount of anti-LG3 antibodies (who are more likely to benefit from the treatment).
- groups such as a low-risk group, a medium-risk group and a high-risk group or into quadrants or quintiles, the lowest quadrant or quintile being individuals with the lowest amount of anti-LG3 antibodies (who are less likely to benefit from the treatment) and the highest quadrant or quintile being individuals with the highest amount of anti-LG3 antibodies (who are more likely to benefit from the treatment).
- control levels according to the invention may be, in addition to predetermined levels or standards, anti-LG3 antibody levels measured in other samples (e.g. from healthy/normal subjects) tested in parallel with the experimental sample.
- control level is a corresponding level or standard established based on anti-LG3 antibody levels in subjects not suffering from vascular damage or acute vascular rejection (AVR), or not at risk of suffering from vascular damage or AVR.
- AVR acute vascular rejection
- higher anti-LG3 antibody levels measured in a sample from subject relative to the control level is indicative that the subject is suffering from vascular damage or AVR, or is at risk (or is at high risk) of suffering from vascular damage or AVR (i.e.
- anti-LG3 levels measured in a sample from subject relative to the control level is indicative that the subject is not suffering from vascular damage or AVR, or is not at risk (or is at low risk) of suffering from acute vascular rejection (i.e., who is less likely to benefit from the treatment).
- control level is a corresponding level or standard established based on anti-LG3 levels in subjects known to suffer from vascular damage or AVR, or known to be at risk of suffering from AVR.
- similar or higher anti-LG3 levels measured in a sample from the subject relative to the control level is indicative that the subject is suffering from vascular damage or AVR, or is at risk (or at high risk) of suffering from acute vascular rejection (i.e., who is more likely to benefit from the treatment)
- lower anti-LG3 levels measured in a sample from subject relative to the control level is indicative that the subject is not suffering from vascular damage or AVR, or is not at risk (or is at low risk) of suffering from acute vascular rejection (i.e., who is less likely to benefit from the treatment).
- the term "subject”, “patient” or “recipient” is meant to refer to any animal, such as a mammal including human, mice, rat, dog, cat, pig, cow, monkey, horse, etc. In an embodiment, the above-mentioned "subject”, “patient” or “recipient” is a mammal, in a further embodiment a human.
- the term "transplant recipient” as used herein refers to a subject who has already received solid organ transplantation, or who is a candidate for receiving solid organ transplantation (i.e. who will be undergoing solid organ transplantation because of a medical condition).
- the above-mentioned solid organ transplant is a kidney/renal transplant, a heart transplant recipient, a lung transplant or a pancreas transplant.
- the transplant recipient suffers from acute vascular rejection or is at risk of (i.e., has a predisposition for) suffering from acute/active vascular rejection.
- the above-mentioned acute vascular rejection is a Banff 97 classification grade I la, lib and/or III acute vascular rejection or an acute, antibody-mediated rejection.
- the Banff 97 classification is an internationally recognized classification system for the diagnosis of renal allograft pathology (Racusen et a/., Kidney International 55 (1999), pp. 713-723).
- Grade I Is typically defines cases with mild to moderate intimal arteritis (v1); grade lib typically defines cases with several intimal arteritis comprising > 25% of the luminal area (v2); and grade III typically defines cases with transmural arteritis and/or arterial fibrinoid change and necrosis of medial smooth muscle cells (v3 with accompanying lymphoctic inflammation).
- Antibody-mediated rejection is characterized by positive C4d staining in the graft peritubular capillaries, in the presence of anti-donor specific antibody (anti-HLA) in the circulation, a histologic appearance of acute tubular necrosis, peritubular capillaritis, glomerulitis or endarteritis.
- anti-HLA anti-donor specific antibody
- the above-mentioned method prevents acute or subacute vascular rejection in said transplant recipient.
- the above-mentioned method prevents acute vascular rejection in said transplant recipient.
- the present invention provides the use of a ligand that binds to anti-
- LG3 antibodies in extracorporeal anapheresis or plasmapheresis for preventing or decreasing vascular inflammation and/or obliterative remodeling in an allogeneic solid organ transplant recipient.
- the ligand that binds to anti-LG3 antibodies is as defined above.
- the present invention provides the use of an LG3 polypeptide in extracorporeal anapheresis or plasmapheresis for preventing or decreasing vascular inflammation and/or obliterative remodeling in an allogeneic solid organ transplant recipient.
- the above-mentioned method/use may be combined with other treatments for solid organ graft rejection, for example immunosuppressive agents currently used to prevent or treat acute rejection of solid organ transplant, such as calcineurin inhibitor (CNI) drugs (e.g., cyclosporine A, tacrolimus), corticosteroids (e.g., methylprednisolone), antiproliferative agents (e.g., mycophenolate mofetil or MMF, azathioprine), mammalian-target- of-rapamycin (mTOR) inhibitors (e.g., sirolimus), and immunomodulatory agents (e.g., anti- CD20 antibodies that induces depletion of B-cells such as RituximabTM, antibodies directed against complement proteins such as EculizumabTM).
- CNI calcineurin inhibitor
- mTOR mammalian-target- of-rapamycin
- sirolimus e.g., sirolimus
- immunomodulatory agents
- the present invention provides a kit for preventing or decreasing vascular inflammation and/or obliterative remodeling in an allogeneic solid organ transplant recipient, said kit comprising a ligand that binds to anti-LG3 antibodies attached to, or immobilized on, a solid support.
- the ligand that binds to anti-LG3 antibodies and the solid support are as defined above.
- the present invention provides a kit for preventing or decreasing vascular inflammation and/or obliterative remodeling in an allogeneic solid organ transplant recipient, said kit comprising an LG3 polypeptide attached to, or immobilized on, a solid support.
- the kit may be used for partial or complete removal of anti-LG3 antibodies from a body fluid, specifically from blood, specifically from cell containing or cell-free blood fractions, more specifically from plasma.
- Such kit may further comprise, for example, instructions setting forth the above-mentioned methods (i.e., instructions for preventing or decreasing vascular inflammation and/or obliterative remodeling in an allogeneic solid organ transplant recipient using the kit), containers (e.g., a column), reagents useful for performing the methods (e.g., buffers, enzymes, solutions, etc.), and the like.
- the ligand that binds to anti-LG3 antibodies and the solid support are in a column.
- the present invention provides an affinity chromatography column comprising the ligand that binds to anti-LG3 antibodies and the solid support.
- a kit or affinity chromatography column may be incorporated into an apheresis or plasmapheresis device.
- the present invention provides an apheresis or plasmapheresis device comprising the above-noted kit or chromatography column.
- the present invention provides the use of the above-mentioned kit or affinity chromatography column for preventing or decreasing vascular inflammation and/or obliterative remodeling in an allogeneic solid organ transplant recipient.
- Example 1 Materials and Methods
- mice Animals and aorta transplantation procedures.
- Adult C57BI/6 and BALB/c mice (20-25 g) (Charles River, St-Constant, QC) were maintained on a 12-hour light-dark cycle and fed a normal diet ad libitum. Mice were anaesthetized using isoflurane (2%) by inhalation.
- Aortic transplantation was performed as described elsewhere with minor modifications (Koulack J et al., Microsurgery 1995; 16:1 10-1 13; Shimizu K, et al.
- Naive non-transplanted C57BI/6 mice were injected subcutaneously with either recombinant LG3 (50 ⁇ ) or PBS, emulsified in incomplete Freund's adjuvant (IFA), every 2 weeks for a total of 3 immunizations. Blood was harvested with cardiac puncture at sacrifice 12-14 days after the last immunization. Sera (diluted 1/100) were tested for the presence of anti-LG3 as described.
- IgG were isolated from pooled sera of either LG3-immunized mice (anti-LG3 IgG) or PBS-immunized mice (control IgG) using protein A SepharoseTM CL-4B (Sigma-Aldrich), and quantitated by Micro BCA assay (Pierce, Rockford, IL, USA).
- anti-LG3 IgG a group of mice received tail vein intravenous injections of either 50 ⁇ g anti-LG3 IgG or 50 ⁇ g of control IgG. Each group received injections every other day during three weeks post-transplantation for a total of 8 doses.
- Immunohistochemistry Transplanted and adjacent native aortas were harvested at 3 weeks post-transplantation. Tissues were fixed with 10% neutral buffered formalin and paraffin embedded according to usual methods. Samples were cut into 4 ⁇ slices. Immunohistochemistry was assessed on an immunostainer (DiscoveryTM XT system, Ventana Medical Systems, Arlington, AZ) according to manufacturer's recommendations. Antigen retrieval was performed with proprietary reagents. When mentioned, samples were stained with haematoxylin-eosin (H&E).
- H&E haematoxylin-eosin
- NK cells T cells or C4d deposition
- indirect immunoperoxidase staining was performed using the primary anti-asialo GM 1 anti body (1/2000, Wako), anti-CD3 antibody (1/50, AbD SerotecTM MCA1477) or anti-C4d (1/50, Biomedica) respectively followed by incubation with specific secondary biotinylated antibodies. Streptavidin horseradish peroxidase, and 3,3-diaminobenzidine were used according to the manufacturer's instructions (DABmapTM detection kit, Ventana Medical Systems). Finally, sections were counterstained with haematoxylin.
- NK cells or macrophages For the detection of NK cells or macrophages (FIGs. 12A and B), indirect immunoperoxidase staining was performed using the primary anti-asialo GM 1 antibody (1/2000, Wako) and anti-F4/80 antibody, respectively followed by incubation with specific secondary biotinylated antibodies. Streptavidin horseradish peroxidase, and 3,3-diaminobenzidine were used according to the manufacturer's instructions (DABmap® detection kit, Ventana Medical Systems). Finally, sections were counterstained with haematoxylin. Digital images of stained tissues were captured by Leica® DMLS microscope and Leica® DFC420C camera (Leica Microsystems, Richmond Hill, ON).
- Anti-LG3 measurements Anti-LG3 titers were measured with a locally-developed ELISA. Recombinant mouse LG3 (10 nanograms/microliter) was first coated on 96-well Immulonll HB plates (Thermo Electron, Waltham, MA), for a total of 1 ,000 nanograms per well. The sera were diluted (1/100), and 100 microliters were added per well. The plates were washed, and bound IgGs were detected using horseradish peroxidase coupled anti-mouse IgG antibody (Amersham, Baie d'Urfe, QC).
- Conditioned media from serum starved HUVECs apoptotic was fractionated using sequential centrifugation 1) 1200 x g 15 min. to remove cellular debris 2) 50 000 x g, 15 min. to pellet apoptotic bodies, 3) 200 000 x g, 18h to pellet nanovesicles. Apoptotic bodies and nanovesicles pellets were collected and resuspended in a volume serum-free medium corresponding to the initial volume of conditioned medium.
- Aortic transplantation and histology (apoptotic bodies and nanovesicles experiments).
- Adult C57BI/6 and BALB/c mice were purchased from Charles River. Aortic transplantation was performed as described previously (Soulez M. et al. Circ Res. 2012 Jan 6;110(1):p. 94-104).
- a 6-mm segment of flushed abdominal aorta from BALB/c mice were transplanted in C57BI/6 mice in the orthotopic position with end-to-end anastomoses. Mice were injected every other day post transplantation with nanovesicles and or apoptotic bodies (150 ⁇ ) up to 8 injections.
- Transplanted and adjacent native aortae were harvested at 3 weeks, embedded in paraffin, and processed for light microscopy with hematoxylin-eosin (H&E) staining.
- Digital images of stained tissues were captured by LeicaTM DMLS microscope and LeicaTM DFC420C camera (Leica Microsystems, Richmond Hill, ON).
- Intimal and medial areas of the aortic grafts were outlined and quantified with a digital image analysis program (ImageJTM 1 .42q, NIH, Bethesda, MD).
- Detection of anti-LG3 antibodies apoptotic bodies and nanovesicles experiments.
- Murine anti-LG3 antibodies were detected by ELISA using recombinant LG3 as the antigen.
- Sera were diluted (1/100) to perform the assay.
- Specific antibodies to LG3 were detected with anti-mouse IgG antibody coupled with horseradish peroxidase (HRP), followed by revelation tetramethylbenzidine substrate which was stopped with sulfuric acid.
- HRP horseradish peroxidase
- Spectrophotometric analysis was performed at 450nm and titers are expressed as optical density (OD).
- Murine EC were isolated from the aorta of C57BI/6 mice, and grown in Dulbecco's Modified Eagle Medium (DMEM), low glucose culture media supplemented with endothelial cell growth supplements (ECGS), 10% FBS, 10% calf serum, 1 % penicillin-streptomycin and 1 % fungizone. To generate conditioned medium, cells were exposed to serum free medium for 8H. For all experiments, equal volumes of media conditioned by an equal number of cells were compared. We demonstrated in previous work that this system leads to the release of active mediators by apoptotic endothelial cells downstream of caspase-3 activation without cell membrane permeabilisation (Sirois I. et al. Cell Death Differ. 201 1 ; 18(3):p. 549-62).
- mice received tail vein (150 ⁇ _) IV injections of resuspended isolated vesicles. Each group received injections every other day during three weeks post-transplantation for a total of 8 doses.
- Example 2 Anti-LG3 antibodies increase obliterative remodeling in a murine model of vascular rejection
- a murine model of pure vascular rejection based on orthotopic transplantation of a fully MHC-mismatched aortic segment, was used to determine whether anti-LG3 behaves as an accelerator of allograft vascular injury.
- Transplantation of a fully MHC-mismatched aortic segment in absence of immunosuppression leads to subacute vascular inflammation and myointimal thickening progressing over 9 weeks (Soulez M, et al.
- Vascular inflammation and neointima formation were specific to the allogeneic aorta, as the native aorta adjacent to the allograft did not show leukocyte infiltration or neointima formation (FIG. 4).
- DSA donor-specific antibody
- murine anti-LG3 IgGs or control IgGs were passively transferred to recipients of an allogeneic aortic graft exposed, or not, to 15 minutes of ischemia prior to transplantation. Fifteen minutes of ischemic preconditioning was chosen as this condition does not induce vascular remodeling or inflammation per se. Purified anti-LG3 or control IgG were passively transferred intravenously to aortic allograft recipients every other day for three weeks post-transplantation. Anti-LG3 IgG titers (predominantly lgG1 and lgG2b, FIG.
- Example 3 Apoptotic bodies inhibit the production of anti-LG3 antibodies and neointima formation that is triggered by the injection of apoptotic membrane nanovesicles
- LG3 is released by apoptotic EC through caspase-3-dependent pathways and murine caspase-3 -/- EC release significantly less LG3 when exposed to a pro-apoptotic stimulus as compared to wild-type EC (FIG. 10A).
- a novel type of membrane vesicles produced by apoptotic EC downstream of caspase-3 has been recently characterized (Sirois, I., et al., Cell Death Differ, 201 1. 18(3): p. 549-62). These membrane vesicles are functionally, structurally and biochemically distinct from classic apoptotic bodies and share common ultrastructural and biochemical markers with exosomes (FIG. 10B).
- Apoptotic bodies stem from blebbing of the cell membrane and their diameter ranges from 50 to 500 nm. Exosomes are secreted through fusion of multivesicular bodies with the cell membrane, range in size from 30 to 100 nm and present with a cup-shape morphology when evaluated by electron microscopy. (Sirois, I., et al., 201 1 , supra; Pallet, N., et al., Am J Transplant, 2012. 12(6): p. 1378-84; Thery, C, et al., Nat Rev Immunol, 2009. 9(8): p. 581-93). FIG.
- FIG. 10B shows membrane nanovesicles derived from apoptotic endothelial cells that share similarities with exosomes, such as size and morphology.
- an unbiased proteomic screen was performed where the proteomes of endothelial apoptotic bodies and apoptotic nanovesicles was compared.
- LG3 was identified within both apoptotic bodies and apoptotic nanovesicles produced by serum starved apoptotic EC (FIG. 10C). Confocal microscopy confirmed the presence of LG3 within membrane vesicles released by apoptotic EC (FIG. 10D).
- mice transplanted with an allogeneic aortic graft were injected intravenously with either vehicle, apoptotic nanovesicles alone, apoptotic bodies alone, or medium containing both apoptotic bodies and membrane nanovesicles.
- FIG. 1 1A and B Furthermore, infiltration of macrophages (F4/80) (FIG.
- FIG. 12A p ⁇ 0.05
- NK cells Asialo
- FIG. 12B p ⁇ 0.05
- LG3 is present in apoptotic nanovesicles from endothelial cells, is highly antigenic, and identify the release of apoptotic nanovesicles during endothelial death as a potential mechanism implicated in the production of anti-LG3 antibodies, neointima formation, and vascular injury and inflammation.
- Apoptotic bodies however tend to inhibit the production of anti-LG3 and vascular injury when mixed with apoptotic nanovesicles.
- This data provides evidence that apoptotic bodies, and more particularly apoptotic bodies derived from ECs, could be used for developing novel methods of inhibiting the production of anti-LG3 antibodies and decrease the severity of vascular injury in transplant recipients experiencing acute vascular rejection.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Transplantation (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Vascular Medicine (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Methods, uses and kits for preventing or decreasing vascular inflammation and/or obliterative remodeling in an allogeneic solid organ transplant recipient, by decreasing the levels of, or neutralizing, anti-LG3 antibodies in the transplant recipient are disclosed.
Description
ANTI-LG3 ANTIBODY INHIBITION IN THE PREVENTION AND/OR TREATMENT OF VASCULAR REJECTION AND RELATED DISEASES AND CONDITIONS
CROSS REFERENCE TO RELATED APPLICATIONS
The present application claims the benefit of United States Provisional Application serial No. 61/729,476, filed on November 23, 2012, which is incorporated herein by reference in its entirety.
TECHNICAL FIELD
The present invention generally relates to vascular damage and transplant rejection, and more specifically to the prevention and/or of vascular damage and/or acute vascular rejection and related diseases and conditions.
BACKGROUND ART
Rejection of transplanted organs is the main barrier of transplantation today. It occurs as a result of humoral and cell-mediated responses by the recipient to specific antigens present in the donor tissue. These antigens are known as major histocompatibility complex (MHC) molecules. In humans, this group of molecules is referred to as human leukocyte antigen (HLA) complex molecules.
Acute rejection usually occurs within the first weeks after transplantation. It is typically caused by mismatched HLA antigens that are present on all cells, which leads to activation of T cells in the host (or transplant recipient). HLA antigens are polymorphic therefore the chance of a perfect match is extremely rare. Endothelial cells in vascularized grafts such as kidneys are typically the earliest victims of acute rejection. Damage to the endothelial lining is often an early predictor of irreversible acute graft failure. The risk of acute rejection is highest in the first 3 months after transplantation, and is lowered by immunosuppressive agents in maintenance therapy.
Several antibodies against non-human leukocyte antigen (HLA) targets have been detected post- and/or pre-transplantation in renal transplantation and chronic renal allograft injury, and thus may be useful as diagnosis and/or prognosis markers (see, e.g., Li et a/., Proc. Natl. Acad. Sci. USA, 106(1 1): 4148-4153, 2009; Sigdel et a/., J Am Soc Nephrol 23: 750-763, 2012, PCT publication No. WO 201 1/109909). However, the role of these non-HLA antibodies in allograft rejection is unclear.
The incidence of acute cellular rejection of renal allografts has decreased over the past decade (USRDS Annual Data Report, 2009). This has been attributed at least in part to the use of new immunosuppressive agents with higher potency on T-cell mediated responses. However, the incidence of acute rejection with evidence of vascular injury (i.e., transplant arteritis or
capillaritis and/or C4d deposition) has not been positively impacted (USRDS Annual Data Report, 2009). In most if not all forms of acute vascular rejection (AVR) of solid organ transplants, immune-mediated endothelial injury leading to a significant apoptotic response is a major characteristic (Solez, K., et a/., Am J Transplant, 2008. 8(4): p. 753-60; Shimizu, A., et a/., Kidney Int, 2000. 58: p. 2546-58; Shimizu, A., et a/., Lab Invest, 2002. 82(6): p. 673-86; Shimizu, A., et a/., Kidney Int, 2002. 61 : p. 1867-1879; Shimizu, A., et al., J Am Soc Nephrol, 2005. 16(9): p. 2732-45).
Immunosuppressive agents currently used to prevent or treat acute rejection of solid- organ transplant, such as calcineurin inhibitor (CNI) drugs (e.g., cyclosporine A, tacrolimus), corticosteroids (e.g., methylprednisolone), anti-proliferative agents (e.g., mycophenolate mofetil or MMF, azathioprine), and mammalian-target-of-rapamycin (mTOR) inhibitors (e.g., sirolimus), generally exhibit poor specificity and thus are associated with several and significant side effects.
There is a need for the development of novel strategies for the prevention and/or treatment of acute vascular rejection, or its associated effects.
The present description refers to a number of documents, the content of which is herein incorporated by reference in their entirety.
SUMMARY OF THE INVENTION
The present invention relates to the following items 1 to 37:
1. A method for preventing or decreasing vascular inflammation and/or obliterative remodeling in an allogeneic solid organ transplant recipient, the method comprising decreasing the level of, or neutralizing, anti-LG3 antibodies in the transplant recipient.
2. The method of item 1 , wherein the method comprises decreasing the level of the anti-LG3 antibodies in the transplant recipient.
3. The method of item 2, wherein the method comprises treating a biological sample comprising anti-LG3 antibodies from the transplant recipient to remove anti-LG3 antibodies from the sample, and reintroducing the biological sample into the transplant recipient.
4. The method of item 3, wherein the treating comprises contacting the biological sample comprising anti-LG3 antibodies from the transplant recipient with a ligand that binds to the anti-LG3 antibodies, and removing the anti-LG3 antibody-ligand complexes from the biological sample.
5. The method of item 4, wherein the ligand is an antibody.
6. The method of item 5, wherein the antibody is an anti-human IgG antibody.
7. The method of item 4, wherein the ligand is an LG3 polypeptide.
8. The method of item 7, wherein the LG3 polypeptide comprises the sequence of SEQ ID NO:2 (FIG. 2C), or a sequence having at least 60% similarity or identity with the sequence of SEQ ID NO:2 (FIG. 2C).
9. The method of item 8, wherein the LG3 polypeptide comprises the sequence of SEQ ID NO:2 (FIG. 2C), or a sequence having at least 80% similarity or identity with the sequence of SEQ ID NO:2 (FIG. 2C).
10. The method of item 9, wherein the LG3 polypeptide comprises the sequence of SEQ ID NO:2 (FIG. 2C).
1 1. The method of any one of items 4 to 10, wherein the ligand is bound onto a solid support.
12. The method of item 1 1 , wherein the solid support is a chromatography resin or matrix.
13. The method of item 1 1 or 12, wherein the solid support is in a chromatography column.
14. The method of any one of items 3 to 13, wherein the biological sample is a blood- derived sample.
15. The method of any one of items 2 to 14, wherein the method is performed during plasmapheresis of the transplant recipient.
16. The method of item 2, wherein the method comprises administering to the transplant recipient an effective amount of autologous apoptotic bodies.
17. The method of item 16, wherein the apoptotic bodies derive from endothelial cells.
18. The method of item 1 , wherein the method comprises neutralizing the anti-LG3 antibodies in the transplant recipient.
19. The method of item 18, wherein the method comprises administering to the transplant recipient an effective amount of an agent that binds to the anti-LG3 antibodies and inhibits their interaction with LG3.
20. The method of item 19, wherein the agent is an antibody.
21. The method of any one of items 1 to 20, wherein the method is performed prior to the transplantation.
22. The method of any one of items 1 to 21 , wherein the method is performed after the transplantation.
23. The method of any one of items 1 to 22, wherein the allogeneic solid organ transplant is from a deceased donor.
24. The method of any one of items 1 to 23, wherein the solid organ is a kidney.
25. The method of any one of items 1 to 24, wherein the method prevents acute vascular rejection in the subject.
26. Use of an agent that neutralizes anti-LG3 antibodies for preventing or decreasing vascular inflammation and/or obliterative remodeling in an allogeneic solid organ transplant recipient.
27. Use of an agent that neutralizes anti-LG3 antibodies for the preparation of a medicament for preventing or decreasing vascular inflammation and/or obliterative remodeling in an allogeneic solid organ transplant recipient.
28. The use of item 26 or 27, wherein the agent is a ligand that binds to the anti-LG3 antibodies and inhibits their interaction with LG3.
29. The use of item 28, wherein the agent is an antibody.
30. A kit for preventing or decreasing vascular inflammation and/or obliterative remodeling in an allogeneic solid organ transplant recipient, the kit comprising a ligand that binds to anti-LG3 antibodies bound to a solid support.
31. The kit of item 30, wherein the solid support is a chromatography resin or matrix.
32. The kit of item 30 or 31 , wherein the kit further comprises a chromatography column.
33. Use of the kit of any one of items 30 to 32 for preventing or decreasing vascular inflammation and/or obliterative remodeling in an allogeneic solid organ transplant recipient.
34. An apheresis or plasmapheresis device comprising a chromatography column, the column comprising a ligand that binds to anti-LG3 antibodies bound to a solid support.
35. Use of autologous apoptotic bodies for preventing or decreasing vascular inflammation and/or obliterative remodeling in an allogeneic solid organ transplant recipient.
36. Use of autologous apoptotic bodies for the preparation of a medicament for preventing or decreasing vascular inflammation and/or obliterative remodeling in an allogeneic solid organ transplant recipient.
37. The use of item 35 or 36, wherein the apoptotic bodies are derived from endothelial cells.
Other objects, advantages and features of the present invention will become more apparent upon reading of the following non-restrictive description of specific embodiments thereof, given by way of example only with reference to the accompanying drawings. BRIEF DESCRIPTION OF DRAWINGS
In the appended drawings:
FIG. 1A shows the structure of perlecan;
FIG. 1 B shows the structure of Domain V/Endorepellin of perlecan, with the C-terminal LG3 domain circled;
FIGs. 2A and 2B show the amino acid sequence of human basement membrane- specific heparan sulfate proteoglycan core protein precursor (also known as perlecan, NCBI
reference sequence No. NP_005520, SEQ ID NO:1), with the putative amino acids forming the LG3 domain (spanning about residues 4201-4389) depicted in bold;
FIG. 2C show the putative amino acid sequence of human LG3 (SEQ ID NO:2);
FIGs. 3A to D show (A) Hematoxylin and eosin (H&E) stained aortic sections of allografts exposed to warm ischemia for 0, 15 or 30 min pretransplantation and harvested 3 weeks post-surgery (magnification: 5X left panels and 20X right panels). (B) Intima/media ratio in allografts exposed to warm ischemia for 0, 15 or 30 min pre-transplantation and harvested 3 weeks post-surgery (n=8, 8 and 7 respectively). (C) Anti-donor IgG titers in sera from allografted mice 1 , 2 and 3 weeks post-surgery (n=8 for each time point) and in isografted mice 3 weeks post-surgery (n=6). Anti-donor antibodies are expressed in arbitrary unit (AU). (D) Anti-donor IgG titers in mice that received an allograft exposed to warm ischemia for 15 min assessed pretransplantation (pre), 10 days and 3 weeks post-surgery (n=8 for each time point). Donor- specific antibody expressed in arbitrary unit (AU);
FIG. 4 shows H&E stained section of adjacent isogenic aorta to an allograft exposed to warm ischemia for 30 min pre-transplantation and harvested 3 weeks post-surgery (magnification: 20X);
FIGs. 5A to 5D show (A) Anti-LG3 IgG titers in mice transplanted with a non-ischemic (no ischemia) or an ischemic allograft (15 min) and passively transferred with control IgG (white bars) or anti-LG3 IgG (black bars) (n=7 for each group) harvested at 1 , 2 or 3 weeks post- surgery. *p<0.01. (B) Anti-donor IgG titers assessed 3 weeks post-surgery in mice transplanted with a non-ischemic (no ischemia) or an ischemic allograft (15 min) and passively transferred with control IgG or anti-LG3 IgG (n=6 per group). (C) Intima/media ratio in mice transplanted with a non-ischemic allograft, passively transferred with control IgG or anti-LG3 IgG and sacrificed 3 weeks post-surgery (n=6 for each group). (D) H&E-stained aortic allografts from mice transplanted with a non-ischemic allograft and passively transferred with control IgG or anti-LG3 IgG (n=6 per group) and sacrificed 3 weeks post-surgery. (Top panels magnification: 5X). The square insert indicates the magnified area (Lower panels, magnification: 40X). The arrow indicates neointima formation;
FIG. 6 shows murine IgG subclasses levels (expressed as optical density X1 ,000) in anti-LG3 IgG used for passive transfer.
FIGs. 7A and 7B show (A) Upper panel: H/E staining and immunohistochemistry for C4d deposition in aortic allograft sections exposed to warm ischemia (15 min) in mice passively transferred with control IgG or anti-LG3 IgG. (magnification: 20X) In: intima. M: Media. The arrow indicates leukocyte infiltration. Lower panel: Intima/media ratio in mice transplanted with an ischemic allograft (15 min) and passively transferred with control IgG or anti-LG3 IgG (n=7 for each group) and sacrificed 3 weeks post-surgery. (B) Upper panels: Immunohistochemistry for the detection CD3 (T cells; top panels) or Asialo GM1 (NK cells: lower panels) positive cells
in aortic allograft sections exposed to warm ischemia (15 min) in mice passively transferred with control IgG or anti-LG3 IgG. (magnification: 20X) In: intima. M: Media. The arrow indicates accumulation either T cells (top panel) or NK cells (lower panel). Lower panels: Average number of CD3 or Asialo GM 1 -positive cells per high power field in allografted mice passively transferred with control IgG or anti-LG3 IgG (n=3 for each group);
FIG. 8 shows H/E staining and immunohistochemistry for C4d deposition in adjacent isogenic aorta sections in allografted mice passively transferred with control IgG or anti-LG3 IgG;
FIG. 9: Left panel: H/E staining and immunohistochemistry for C4d deposition in aortic isograft sections exposed to warm ischemia (15 min) in mice passively transferred with control IgG or anti-LG3 IgG. (magnification: 20X) In: intima. M: Media; Right panel: Intima/media ratio in mice transplanted with an ischemic isograft (15 min) and passively transferred with control IgG or anti-LG3 IgG (n=4 for each group) and sacrificed 3 weeks post-surgery;
FIG. 10A shows that LG3 is released by apoptotic EC through caspase-3-dependent pathways. Media conditioned by wild type (WT) or Caspase 3 -/- (Casp3) murine primary EC cultured in pro-apoptotic conditions (serum-free medium for 4h) analyzed by WB for LG3 release. *p<0.05;
FIG. 10B shows electron micrographs of purified apoptotic nanovesicles and apoptotic bodies from apoptotic HUVEC. Note the difference in scale demonstrating size differences. Nanovesicles present a typical cup-shape morphology;
FIG. 10C shows that LG3 was identified within both apoptotic bodies and apoptotic nanovesicles produced by serum starved apoptotic EC by unbiased proteomic screen where the proteomes of endothelial apoptotic bodies and apoptotic nanovesicles were compared (in collaboration with Dr. Pierre Thibault, Universite de Montreal). Briefly, 12 ug of proteins from apoptotic bodies and nanovesicles were separated by SDS-PAGE and digested by trypsin. Peptides were extracted and separated on a nano-LC column coupled to an LTQ-Orbitrap™ mass spectrometer followed by three product ion scans (MS/MS). The table shows the different LG3 peptides identified.
FIG. 10D shows a confocal microscopy image confirming the presence of LG3 within membrane vesicles released by apoptotic EC. Immunofluorescence micrographs of purified membrane vesicles from apoptotic human EC (cultured in serum free medium for 4h) showing staining of LG3 (light grey) in 20 μΜ apoptotic body as well as in <1 μΜ (arrows) nanovesicles;
FIGs. 11A and 11 B show that in a murine model of vascular rejection, injections of nanovesicles from recipient endothelial apoptotic cells increase anti-LG3 antibody production and early neointima formation. In contrast, injections of apoptotic bodies alone or of combined apoptotic bodies and apoptotic nanovesicles did not increase anti-LG3 titers nor neointima formation. FIG. 11 A: Anti-LG3 titers in sera collected 3 weeks post-surgery from mice injected
i.v. with purified nanovesicles, purified apoptotic bodies or nanovesicles and apoptotic bodies (Nano + apoptotic bodies) from apoptotic serum starved murine endothelial cells (mEC) or vehicle (n=8 for each group). FIG. 11 B: Intima/media ratio in aortic allograft from mice injected i.v. with purified nanovesicles, purified apoptotic bodies or nanovesicles and apoptotic bodies (Nano + apoptotic bodies) from apoptotic serum starved mEC or vehicle (n=8 for each group).
FIGs. 12A and 12B show the average number of Asialo GM 1 (NK cells, FIG. 12A) or F4/80 (macrophages, FIG. 12B) positive cells per high power field in aortic allograft sections from allograft recipients injected i.v. with vehicles, nanovesicles, or nanovesicles and apoptotic bodies (Nano + apoptotic bodies) from apoptotic serum starved mEC (n = 5-25 of high power field per condition, n=1 -5 mice in each group).
DISCLOSURE OF INVENTION
In the studies described herein, the present inventors have demonstrated that anti-LG3 antibodies increase vascular inflammation and obliterative remodeling in a murine model of vascular rejection. They have shown that mice receiving an allogeneic aortic graft exposed to ischemia prior to transplantation and in which anti-LG3 antibodies were passively transferred showed evidence of early neointima formation and increased infiltration of the allograft by mononuclear cells 3 weeks after transplantation.
Accordingly, in a first aspect, the present invention provides a method for preventing or decreasing vascular inflammation and/or obliterative remodeling in an allogeneic solid organ transplant recipient, said method comprising decreasing the level of, or neutralizing, anti-LG3 antibodies in said transplant recipient.
Vascular inflammation following allogeneic solid organ transplant recipient may be measured, for example, by detection mononuclear cell (e.g., T cells, NK cells) infiltration, deposition of complement fragments (e.g., C4d, C1 q), and/or increased cytokine/chemokine secretion. Obliterative remodeling may be determined, for example, by detecting neointima formation (e.g., increased intima-media ratios). Vascular inflammation and/or obliterative remodeling typically occur, for example, during vascular rejection. Thus, in an embodiment, the above-mentioned method prevents or decreases vascular rejection, in a further embodiment acute or subacute vascular rejection, in the transplant recipient. In a further embodiment, the above-mentioned method prevents or decreases acute vascular rejection in the transplant recipient.
In an embodiment, the above-mentioned method comprises (selectively or nonselective^) decreasing the level of said anti-LG3 antibodies in said transplant recipient. In an embodiment, the method comprises treating a biological sample that comprises anti-LG3 antibodies from the transplant recipient to remove the anti-LG3 antibodies (i.e. decreasing the level/amount thereof), and reintroducing the treated biological sample (that contain no or less
anti-LG3 antibodies) into the transplant recipient. "Selectively" decreasing the level of anti-LG3 antibodies means that the level of anti-LG3 antibodies is decreased preferentially relative to other antibodies (either in absolute and/or relative amounts).
In an embodiment, the above-mentioned biological sample is a biological fluid, e.g. , lymph, or a blood-derived sample. The term "blood-derived sample" as used herein refers to blood (e.g. , fresh blood, stored blood) or to a fraction thereof, such as serum, plasma and the like. It also refers to any sample that may be obtained following one or more purification, enrichment, and/or treatment steps using blood (obtained by venous puncture, for example) as starting material. In an embodiment, the above-mentioned blood-derived sample is blood or plasma.
Thus, in an embodiment, the method comprises collecting a biological sample (e.g., blood) from the subject, treating the sample to remove the anti-LG3 antibodies (i.e. decreasing the level/amount thereof), and reintroducing the treated biological sample.
In an embodiment, the treatment comprises contacting the biological sample comprising anti-LG3 antibodies with a ligand that binds to said anti-LG3 antibodies, removing the anti-LG3 antibodies-ligand complexes from the biological sample, and reintroducing the treated biological sample (that contain no or less anti-LG3 antibodies) into the transplant recipient (immunoadsorption).
In an embodiment, the above-mentioned ligand is an antibody. In an embodiment, the antibody non-specifically recognizes anti-LG3 antibodies, i.e. binds to all antibodies present in the sample. In an embodiment, the antibody is an anti-lgG antibody, in a further embodiment an anti-human IgG antibody.
In another embodiment, the antibody specifically recognizes anti-LG3 antibodies, i.e. binds preferentially to anti-LG3 antibodies relative to other antibodies present in the sample. Such a specific antibody may be generated by immunizing an animal with one or more of the complement determining regions (CDR1 , CDR2 and/or CDR3) of anti-LG3 antibodies. Methods to generate antibodies against an antigen are well known in the art.
In another embodiment, the ligand is an LG3 polypeptide. The term "LG3 polypeptide" refers to a polypeptide comprising a sequence corresponding to an LG3 polypeptide (an LG3 polypeptide domain), in a further embodiment a human LG3 polypeptide/protein. LG3 polypeptide/protein as used herein refers to a C-terminal domain of the perlecan polypeptide (FIGs. 1 B and 2A-2B, SEQ ID NO: 1), in an embodiment a domain comprising an amino acid sequence corresponding to about residues 4197 to about residue 4391 of the amino acid sequence of FIGs. 2A and 2B (SEQ ID NO: 1), for example from about residue 4201 to about residue 4389 (FIG. 2C, SEQ ID NO:2), in a further embodiment from about residue 4203 to about residue 4362 of the amino acid sequence of FIGs. 2A and 2B (SEQ ID NO: 1). In embodiments, the ligand may be the entire perlecan polypeptide, or any fragment or variant
thereof that comprises the sequence of the LG3 region, or a sequence having at least 60, 65, 70, 75, 80, 85, 90, or 95% similarity or identity with the sequence of the LG3 region, and that retains the ability to bind to anti-LG3 antibodies present in a transplant recipient. Sequence identity refers to the degree of correspondence between two sequences, or the fraction of amino acids that are the same between two aligned sequences. Sequence similarity refers to the degree of resemblance between two sequences when they are compared, which is be calculated using a suitable similarity matrix, such as the PAM matrix or the BLOSUM matrix. Percent similarity and identity may be determined, for example, using well known algorithms and software. Optimal alignment of sequences for comparisons of identity/similarity may be conducted using a variety of algorithms, such as the local homology algorithm of Smith and Waterman, 1981 , Adv. Appl. Math 2: 482, the homology alignment algorithm of Needleman and Wunsch, 1970, J. Mol. Biol. 48: 443, the search for similarity method of Pearson and Lipman, 1988, Proc. Natl. Acad. Sci. USA 85: 2444, and the computerised implementations of these algorithms (such as GAP, BESTFIT, FASTA and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, Madison, Wl, U.S.A.). Sequence identity may also be determined using the BLAST algorithm, described in Altschul et al., 1990, J. Mol. Biol. 215:403- 10 (using the published default settings). Software for performing BLAST analysis may be available through the National Center for Biotechnology Information.
In an embodiment, the ligand is an LG3 polypeptide/protein fragment. The term "LG3 polypeptide/protein fragment" refers to a portion of the LG3 polypeptide/protein defined above and that is capable of binding to anti-LG3 antibodies present in biological samples from subjects, e.g. , a portion of the LG3 polypeptide/protein preferentially targeted by the anti-LG3 antibodies.
In an embodiment, the LG3 polypeptide comprises the sequence of SEQ ID NO:2 (FIG. 2C), or a sequence having at least 60, 65, 70, 75, 80, 85, 90, 91 , 92, 93, 94, 95, 96, 97, 98 OR 99% similarity or identity with the sequence of SEQ ID NO:2 (FIG. 2C), and retains the ability to bind to anti-LG3 antibodies present in a transplant recipient. In an embodiment, the LG3 polypeptide comprises the sequence of SEQ ID NO:2 (FIG. 2C), or comprises a sequence having at least 60% similarity or identity with the sequence of SEQ ID NO:2 (FIG. 2C). In another embodiment, the LG3 polypeptide comprises the sequence of SEQ ID NO:2 (FIG. 2C), or comprises a sequence having at least 80% similarity or identity with the sequence of SEQ ID NO:2 (FIG. 2C). In another embodiment, the LG3 polypeptide comprises the sequence of SEQ ID NO:2 (FIG. 2C). In embodiments, the LG3 polypeptide may comprise, further to the LG3 polypeptide domain defined above, one more amino acids covalently linked to the amino- and/or carboxy-termini of said LG3 polypeptide domain. The above-mentioned LG3 polypeptide may thus be a chimeric or fusion peptide containing an LG3 polypeptide domain as described herein, linked at its amino- or carboxy-terminal end, or both, to an amino acid sequence of a different
protein or peptide. In an embodiment, the above-mentioned LG3 polypeptide may comprise a peptide moiety, for example for facilitating its purification, detection and/or attachment to a solid support (a "tag", such as a "His-tag" or a GST-tag"). The above-mentioned LG3 polypeptide may comprise any other chemical moiety, which may be useful for example to stabilize, detect and/or purify the LG3 polypeptide.
In an embodiment, the LG3 polypeptide consists of the sequence of SEQ ID NO:2 (FIG. 2C).
In an embodiment, the ligand (e.g., LG3 polypeptide) is bound (covalently or non- covalently) to a solid support. In an embodiment, the ligand is covalently bound to, or immobilized on, a solid support. The ligand (e.g., LG3 polypeptide) may be immobilized to the solid support via a specific binding agent like a chemical group or a peptide group without significantly affecting the specific binding affinity.
In an embodiment, the above-mentioned solid support is a chromatography matrix/resin. The chromatography matrix/resin used according to the invention can be any material known in the art which is suitable for affinity separation, such as for example porous carrier materials, specifically porous solid phase carrier materials. Any conventional carrier material may be used, but is not limited to, agarose, Sepharose™, polysterene, controlled pore glass, dextrans, cellulose, synthetic polymers and copolymers like hydrophilic polymers, porous amorphous silica. The chromatography matrix/resin may be particulate like beads or granules generally used in columns or in sheet form like membranes or filters which may be flat, pleated, hollow fibers or tubes. In an embodiment, the above-mentioned matrix/resin is provided in the form of a column (chromatography column), e.g. , wherein the matrix is packed in a column. Where the resin is a bead, the beads may be provided in various sizes, depending, in part, on the nature of the sample being applied, where suitable bead sizes include from about 10 μηι to about 500 μηι, e.g. , from about 10 μηι to about 200 μηι, from about 20 μηι to about 150 μηι, from about 50 μηι to about 150 μηι. Non-limiting examples of formats in which a matrix is provided include a gravity-flow column; a fast protein liquid chromatographic (FPLC) column; a multi-well (e.g. , 96-well) column format; a spin column; and the like.
In embodiments, binding to the matrix may for example be achieved by column chromatography, batch treatment, or expanded bed absorption approaches. Column chromatography typically entails packing the solid matrix onto a chromatography column and passing the sample through the column to allow binding of the antibodies, the flow through being free or substantially free of antibodies, more particularly anti-LG3 antibodies. Batch treatment typically entails combining the sample (e.g., plasma) with the solid matrix in a vessel, mixing, separating the solid matrix (which contains the ligand/anti-LG3 complexes), and collecting the liquid phase that is free or substantially free of antibodies, more particularly anti- LG3 antibodies.
In an embodiment, the above-mentioned methods are performed in vivo or in vitro, in a further embodiment in vitro.
In an embodiment, the above-mentioned method is performed through/during (extracorporeal) anapheresis or plasmapheresis.
Apheresis is a method wherein the therapeutic effects are based on the extracorporeal elimination of pathogenic proteins, protein-bound pathogenic substances, free pathogenic substances or pathogenic cells of the blood, in case of the present invention it is the removal of anti-LG3 antibodies. If the pathogenic protein can only be eliminated from cell-free plasma, plasma previously is separated from the blood cells by means of a membrane plasma separator (plasma separation) or by means of a haemocentrifuge. In selective whole blood apheresis methods, the anti-LG3 antibodies are specifically adsorbed directly from the non-pretreated blood without a previous plasma separation, whereby, in contrast to the plasma separation methods, both the plasma separation and the addition of a substitution solution can be omitted.
During plasmapheresis, blood is initially taken out of the body through a needle or previously implanted catheter. Plasma is then removed from the blood by a cell separator. Three procedures are commonly used to separate the plasma from the blood:
Discontinuous flow centrifugation: One venous catheter line is used. Typically, a 300 ml batch of blood is removed at a time and centrifuged to separate plasma from blood cells.
Continuous flow centrifugation: Two venous lines are used. This method requires slightly less blood volume to be out of the body at any one time as it is able to continuously spin out plasma.
Plasma filtration: Two venous lines are used. The plasma is filtered using standard hemodialysis equipment. This continuous process requires less than 100 ml of blood to be outside the body at one time.
During immunoadsorption, the blood of a patient is cleared from immunoglobulin (e.g., anti-LG3 antibodies) by an extracorporeal affinity purification step, chromatography column.
After plasma separation, the blood cells are returned to the person undergoing treatment, while the plasma, which contains the antibodies, is first treated and then returned to the patient in traditional plasmapheresis. Medication to keep the blood from clotting (e.g., an anticoagulant) is generally given to the patient during the procedure.
In embodiments, the above-mentioned method comprises: (a) obtaining a sample of blood from the transplant recipient; (b) isolating the plasma from the cellular components from said blood sample; (c) contacting said isolated plasma with a ligand that binds to the anti-LG3 antibodies as described above, whereby anti-LG3 antibodies are retained by the ligand (e.g. bound to a solid support such as a chromatography resin); (d) reintroducing the cellular components isolated from step (b) and the purified plasma from step (c) to the patient, e) and optionally repeating the steps c) and d) at least once.
In embodiments, at least 50%, 60%, 70%, 80%, 85%, 90% or 95% of the anti-LG3 antibodies are removed from the biological sample (e.g., plasma).
In another embodiment, the above-mentioned method comprises administering an effective amount of apoptotic bodies, such as autologous apoptotic bodies, to the transplant recipient. In an embodiment, the apoptotic bodies are derived from endothelial cells. Apoptotic bodies (also called apobodies), are small sealed membrane vesicles that are produced from cells undergoing cell death by apoptosis. The formation of apoptotic bodies is a mechanism preventing leakage of potentially toxic or immunogenic cellular contents of dying cells and prevents inflammation or autoimmune reactions as well as tissue destruction.
Methods to produce/isolate apoptotic bodies or apoptotic bodies-rich medium (ABRM) are well known in art (see, e.g., Example 1 below). For example, to isolate endothelial cell- derived apoptotic bodies, isolated confluent human umbilical vein endothelial cells (HUVECs) may be incubated for a certain period of time (e.g., 12-36 hours, 24 hours) in endothelial basal medium without serum and growth factors to induce apoptosis (in the presence or not of TNFa). Apoptosis may be monitored/characterized by double staining with annexin V-fluorescein isothiocyanate (FITC) and propidium iodide (PI).
Medium from apoptotic HUVECs may be collected and clarified from dead cells and cell debris (e.g., by centrifugation). This HUVEC-derived apoptotic bodies-rich medium (ABRM) may be further centrifuged to isolate the apoptotic bodies. Apoptotic bodies may be characterized by flow cytometry after staining with annexin V-FITC and PI.
In an embodiment, the method comprises neutralizing the anti-LG3 antibodies in the transplant recipient. In an embodiment, the method comprises administering to the transplant recipient an effective amount of an agent that binds to anti-LG3 antibodies and inhibits their interaction with LG3. Without wishing to be bound by any theory, it is believed that allograft injury could foster intragraft expression of LG3 which in turn facilitates anti-LG3 antibody deposition, fuels further anti-LG3 antibody production, and enhances immune activation/inflammation at sites of allograft damages. Therefore, any agent that binds to anti- LG3 antibodies and inhibits their interaction with LG3, thus inhibiting anti-LG3 antibody deposition, would be suitable for preventing or decreasing vascular inflammation and/or obliterative remodeling in an allogeneic solid organ transplant recipient. In an embodiment, the agent is an antibody, for example an antibody that binds to anti-LG3 antibodies and inhibits their interaction with LG3. Such a specific antibody may be generated by immunizing an animal with one or more of the complement determining regions (CDR1 , CDR2 and/or CDR3) of anti-LG3 antibodies. Methods to generate antibodies against an antigen are well known in the art.
In another embodiment, the agent is an LG3 polypeptide fused to a targeting moiety, to tether/attract the anti-LG3 antibodies away from the sites of allograft damages. The targeting
moiety could target the LG3 polypeptide/anti-LG3 antibodies complexes to another organ or tissue (remote from the allograft), in which there is no inflammation.
The transplant may be from a living donor or a deceased donor (cadaveric). As shown in the Examples below, anti-LG3 antibodies appear to be more particularly detrimental in an ischemic microenvironment, which is typically sustained by organs from deceased donors (i.e. typically to a greater extent as compared to organs from living donors). Accordingly, in an embodiment, the transplant is from a deceased donor.
In embodiments, the above-mentioned method may be performed prior to and/or after the transplantation. In a further embodiment, the above-mentioned method is performed prior to the transplantation, so as to eliminate, or decrease the level of, anti-LG3 antibodies in the candidate transplant recipient prior to transplantation. Thus, in another aspect, the present invention provides a method for preventing or decreasing vascular inflammation and/or obliterative remodeling in a candidate allogeneic solid organ transplant recipient, said method comprising decreasing the level of, or neutralizing, anti-LG3 antibodies in said candidate transplant recipient (prior to transplantation).
In an embodiment, the above-mentioned method further comprises measuring or determining the levels of anti-LG3 antibodies in the transplant recipient (e.g., candidate transplant recipient). In another embodiment, the method further comprises selecting a transplant recipient (e.g., candidate transplant recipient) having elevated or increased levels of anti-LG3 antibodies, relative to a control level. Methods to measure the levels of anti-LG3 antibodies in a subject are described, for example, in PCT publication No. WO 201 1/109909.
The values for anti-LG3 levels can be absolute or relative values, e.g. , values provided in comparison to control levels. The values for expression levels can be raw values, or values that are optionally rescaled, filtered and/or normalized. The approach used will depend, for example, on the intended use for the data. The values for anti-LG3 levels may correspond to the intensity of a signal measured using a suitable device (e.g. , optical density (OD) values at a given wavelength measured using a spectrometer), or to an estimated anti-LG3 levels (based on a standard curve established using known concentrations of anti-LG3, for example).
"Control level" or "reference level" or "standard level" are used interchangeably herein and broadly refers to a separate baseline level measured in a comparable control sample, which is generally from a subject not suffering from vascular damage or acute vascular rejection or not at risk of suffering from vascular damage or acute vascular rejection. The corresponding control level may be a level corresponding to an average/mean or median level calculated based of the levels measured in several reference or control subjects (e.g. , a pre-determined or established standard level). The control level may be a pre-determined "cut-off value recognized in the art or established based on levels measured in one or a group of control subjects. The corresponding reference/control level may be adjusted or normalized for age,
gender, race, or other parameters. The "control level" can thus be a single number/value, equally applicable to every patient individually, or the control level can vary, according to specific subpopulations of patients. Thus, for example, older men might have a different control level than younger men, and women might have a different control level than men. The predetermined standard level can be arranged, for example, where a tested population is divided equally (or unequally) into groups, such as a low-risk group, a medium-risk group and a high-risk group or into quadrants or quintiles, the lowest quadrant or quintile being individuals with the lowest amount of anti-LG3 antibodies (who are less likely to benefit from the treatment) and the highest quadrant or quintile being individuals with the highest amount of anti-LG3 antibodies (who are more likely to benefit from the treatment).
It will also be understood that the control levels according to the invention may be, in addition to predetermined levels or standards, anti-LG3 antibody levels measured in other samples (e.g. from healthy/normal subjects) tested in parallel with the experimental sample.
In an embodiment, the control level is a corresponding level or standard established based on anti-LG3 antibody levels in subjects not suffering from vascular damage or acute vascular rejection (AVR), or not at risk of suffering from vascular damage or AVR. In such a case, higher anti-LG3 antibody levels measured in a sample from subject relative to the control level is indicative that the subject is suffering from vascular damage or AVR, or is at risk (or is at high risk) of suffering from vascular damage or AVR (i.e. who is more likely to benefit from the treatment), whereas similar or lower anti-LG3 levels measured in a sample from subject relative to the control level is indicative that the subject is not suffering from vascular damage or AVR, or is not at risk (or is at low risk) of suffering from acute vascular rejection (i.e., who is less likely to benefit from the treatment).
In another embodiment, the control level is a corresponding level or standard established based on anti-LG3 levels in subjects known to suffer from vascular damage or AVR, or known to be at risk of suffering from AVR. In such a case, similar or higher anti-LG3 levels measured in a sample from the subject relative to the control level is indicative that the subject is suffering from vascular damage or AVR, or is at risk (or at high risk) of suffering from acute vascular rejection (i.e., who is more likely to benefit from the treatment), whereas lower anti-LG3 levels measured in a sample from subject relative to the control level is indicative that the subject is not suffering from vascular damage or AVR, or is not at risk (or is at low risk) of suffering from acute vascular rejection (i.e., who is less likely to benefit from the treatment).
As used herein the term "subject", "patient" or "recipient" is meant to refer to any animal, such as a mammal including human, mice, rat, dog, cat, pig, cow, monkey, horse, etc. In an embodiment, the above-mentioned "subject", "patient" or "recipient" is a mammal, in a further embodiment a human. The term "transplant recipient" as used herein refers to a subject who has already received solid organ transplantation, or who is a candidate for receiving solid
organ transplantation (i.e. who will be undergoing solid organ transplantation because of a medical condition). In a further embodiment, the above-mentioned solid organ transplant is a kidney/renal transplant, a heart transplant recipient, a lung transplant or a pancreas transplant. In an embodiment, the transplant recipient suffers from acute vascular rejection or is at risk of (i.e., has a predisposition for) suffering from acute/active vascular rejection. In an embodiment, the above-mentioned acute vascular rejection is a Banff 97 classification grade I la, lib and/or III acute vascular rejection or an acute, antibody-mediated rejection. The Banff 97 classification is an internationally recognized classification system for the diagnosis of renal allograft pathology (Racusen et a/., Kidney International 55 (1999), pp. 713-723). Grade I Is typically defines cases with mild to moderate intimal arteritis (v1); grade lib typically defines cases with several intimal arteritis comprising > 25% of the luminal area (v2); and grade III typically defines cases with transmural arteritis and/or arterial fibrinoid change and necrosis of medial smooth muscle cells (v3 with accompanying lymphoctic inflammation). Antibody-mediated rejection is characterized by positive C4d staining in the graft peritubular capillaries, in the presence of anti-donor specific antibody (anti-HLA) in the circulation, a histologic appearance of acute tubular necrosis, peritubular capillaritis, glomerulitis or endarteritis. In an embodiment, the above-mentioned method prevents acute or subacute vascular rejection in said transplant recipient. In a further embodiment, the above-mentioned method prevents acute vascular rejection in said transplant recipient.
In another aspect, the present invention provides the use of a ligand that binds to anti-
LG3 antibodies in extracorporeal anapheresis or plasmapheresis for preventing or decreasing vascular inflammation and/or obliterative remodeling in an allogeneic solid organ transplant recipient. The ligand that binds to anti-LG3 antibodies is as defined above. In an embodiment, the present invention provides the use of an LG3 polypeptide in extracorporeal anapheresis or plasmapheresis for preventing or decreasing vascular inflammation and/or obliterative remodeling in an allogeneic solid organ transplant recipient.
In embodiments, the above-mentioned method/use may be combined with other treatments for solid organ graft rejection, for example immunosuppressive agents currently used to prevent or treat acute rejection of solid organ transplant, such as calcineurin inhibitor (CNI) drugs (e.g., cyclosporine A, tacrolimus), corticosteroids (e.g., methylprednisolone), antiproliferative agents (e.g., mycophenolate mofetil or MMF, azathioprine), mammalian-target- of-rapamycin (mTOR) inhibitors (e.g., sirolimus), and immunomodulatory agents (e.g., anti- CD20 antibodies that induces depletion of B-cells such as Rituximab™, antibodies directed against complement proteins such as Eculizumab™).
In another aspect, the present invention provides a kit for preventing or decreasing vascular inflammation and/or obliterative remodeling in an allogeneic solid organ transplant recipient, said kit comprising a ligand that binds to anti-LG3 antibodies attached to, or
immobilized on, a solid support. The ligand that binds to anti-LG3 antibodies and the solid support are as defined above. In an embodiment, the present invention provides a kit for preventing or decreasing vascular inflammation and/or obliterative remodeling in an allogeneic solid organ transplant recipient, said kit comprising an LG3 polypeptide attached to, or immobilized on, a solid support. The kit may be used for partial or complete removal of anti-LG3 antibodies from a body fluid, specifically from blood, specifically from cell containing or cell-free blood fractions, more specifically from plasma. Such kit may further comprise, for example, instructions setting forth the above-mentioned methods (i.e., instructions for preventing or decreasing vascular inflammation and/or obliterative remodeling in an allogeneic solid organ transplant recipient using the kit), containers (e.g., a column), reagents useful for performing the methods (e.g., buffers, enzymes, solutions, etc.), and the like. In an embodiment, the ligand that binds to anti-LG3 antibodies and the solid support are in a column. Accordingly, in another aspect, the present invention provides an affinity chromatography column comprising the ligand that binds to anti-LG3 antibodies and the solid support. Such a kit or affinity chromatography column may be incorporated into an apheresis or plasmapheresis device. In another aspect, the present invention provides an apheresis or plasmapheresis device comprising the above-noted kit or chromatography column.
In another aspect, the present invention provides the use of the above-mentioned kit or affinity chromatography column for preventing or decreasing vascular inflammation and/or obliterative remodeling in an allogeneic solid organ transplant recipient.
MODE(S) FOR CARRYING OUT THE INVENTION
The present invention is illustrated in further details by the following non-limiting examples. Example 1 : Materials and Methods
Animals and aorta transplantation procedures. Adult C57BI/6 and BALB/c mice (20-25 g) (Charles River, St-Constant, QC) were maintained on a 12-hour light-dark cycle and fed a normal diet ad libitum. Mice were anaesthetized using isoflurane (2%) by inhalation. Aortic transplantation was performed as described elsewhere with minor modifications (Koulack J et al., Microsurgery 1995; 16:1 10-1 13; Shimizu K, et al. Nat Med 2001 ; 7:738-741) In brief, 1 ml of heparinized saline (50 μΙ/ml) was injected into the vena cava to flush the aorta. A 6-mm segment of abdominal aorta from below the renal arteries to just above the aortic bifurcation was excised and soaked in ice-cold 0.9% normal saline. When mentioned, warm ischemia was induced by clamping the aorta for 15 or 30 min before the excision from the donor. The grafts were then excised and sutured orthotopically with end-to-end anastomoses, using 11-0 nylon interrupted sutures.
Production and passive transfer of murine anti-LG3 IgG. Naive non-transplanted C57BI/6 mice were injected subcutaneously with either recombinant LG3 (50 μς) or PBS, emulsified in incomplete Freund's adjuvant (IFA), every 2 weeks for a total of 3 immunizations. Blood was harvested with cardiac puncture at sacrifice 12-14 days after the last immunization. Sera (diluted 1/100) were tested for the presence of anti-LG3 as described. IgG were isolated from pooled sera of either LG3-immunized mice (anti-LG3 IgG) or PBS-immunized mice (control IgG) using protein A Sepharose™ CL-4B (Sigma-Aldrich), and quantitated by Micro BCA assay (Pierce, Rockford, IL, USA). For passive transfer of anti-LG3 IgG, transplanted mice received tail vein intravenous injections of either 50 μg anti-LG3 IgG or 50 μg of control IgG. Each group received injections every other day during three weeks post-transplantation for a total of 8 doses.
Immunohistochemistry. Transplanted and adjacent native aortas were harvested at 3 weeks post-transplantation. Tissues were fixed with 10% neutral buffered formalin and paraffin embedded according to usual methods. Samples were cut into 4 μηι slices. Immunohistochemistry was assessed on an immunostainer (Discovery™ XT system, Ventana Medical Systems, Tucson, AZ) according to manufacturer's recommendations. Antigen retrieval was performed with proprietary reagents. When mentioned, samples were stained with haematoxylin-eosin (H&E). For the detection of NK cells, T cells or C4d deposition, indirect immunoperoxidase staining was performed using the primary anti-asialo GM 1 anti body (1/2000, Wako), anti-CD3 antibody (1/50, AbD Serotec™ MCA1477) or anti-C4d (1/50, Biomedica) respectively followed by incubation with specific secondary biotinylated antibodies. Streptavidin horseradish peroxidase, and 3,3-diaminobenzidine were used according to the manufacturer's instructions (DABmap™ detection kit, Ventana Medical Systems). Finally, sections were counterstained with haematoxylin. Digital images of stained tissues were captured by Leica™ DMLS microscope and Leica™ DFC420C camera (Leica Microsystems, Richmond Hill, ON). Intimal and medial areas grafts were outlined and quantified with a digital image analysis program (ImageJ™ 1 .42q, NIH, Bethesda, MD).
For the detection of NK cells or macrophages (FIGs. 12A and B), indirect immunoperoxidase staining was performed using the primary anti-asialo GM 1 antibody (1/2000, Wako) and anti-F4/80 antibody, respectively followed by incubation with specific secondary biotinylated antibodies. Streptavidin horseradish peroxidase, and 3,3-diaminobenzidine were used according to the manufacturer's instructions (DABmap® detection kit, Ventana Medical Systems). Finally, sections were counterstained with haematoxylin. Digital images of stained tissues were captured by Leica® DMLS microscope and Leica® DFC420C camera (Leica Microsystems, Richmond Hill, ON).
Measurement of murine anti-donor IgG. Sera were diluted 1 : 10 in FACS buffer and incubated with 1x 106 BALB/c splenocyte targets for 30 minutes at 4°C. The samples were then
washed three times and stained with PE goat anti-mouse IgG (1 : 100), Alexa™ 488 anti-mouse CD3e (1 : 100) (BD Biosciences) in FACS buffer for 30 minutes at 4°C, in the dark. Samples were run on a flow cytometer (FACScan™, Becton-Dickinson) and analyzed on computer software (FACS DIVA™, Becton-Dickinson). CD3+ parent gate was utilized to avoid nonspecific background signal due to Fc receptor-expressing cells.
Anti-LG3 measurements. Anti-LG3 titers were measured with a locally-developed ELISA. Recombinant mouse LG3 (10 nanograms/microliter) was first coated on 96-well Immulonll HB plates (Thermo Electron, Waltham, MA), for a total of 1 ,000 nanograms per well. The sera were diluted (1/100), and 100 microliters were added per well. The plates were washed, and bound IgGs were detected using horseradish peroxidase coupled anti-mouse IgG antibody (Amersham, Baie d'Urfe, QC). Reactions were revealed with 100 microliters of tetramethylbenzidine substrate (BD Biosciences) for 10 min, and stopped with 50 microliters of sulfuric acid (H2S04). Spectrophotometric analysis was undertaken at 450 nanometers, and the results were expressed as optical density X1 ,000.
Conditioned medium fractionation and apoptotic bodies and nanovesicles isolation.
Conditioned media from serum starved HUVECs apoptotic was fractionated using sequential centrifugation 1) 1200 x g 15 min. to remove cellular debris 2) 50 000 x g, 15 min. to pellet apoptotic bodies, 3) 200 000 x g, 18h to pellet nanovesicles. Apoptotic bodies and nanovesicles pellets were collected and resuspended in a volume serum-free medium corresponding to the initial volume of conditioned medium.
Aortic transplantation and histology (apoptotic bodies and nanovesicles experiments). Adult C57BI/6 and BALB/c mice were purchased from Charles River. Aortic transplantation was performed as described previously (Soulez M. et al. Circ Res. 2012 Jan 6;110(1):p. 94-104). Very briefly, a 6-mm segment of flushed abdominal aorta from BALB/c mice were transplanted in C57BI/6 mice in the orthotopic position with end-to-end anastomoses. Mice were injected every other day post transplantation with nanovesicles and or apoptotic bodies (150 μΙ) up to 8 injections. Transplanted and adjacent native aortae were harvested at 3 weeks, embedded in paraffin, and processed for light microscopy with hematoxylin-eosin (H&E) staining. Digital images of stained tissues were captured by Leica™ DMLS microscope and Leica™ DFC420C camera (Leica Microsystems, Richmond Hill, ON). Intimal and medial areas of the aortic grafts were outlined and quantified with a digital image analysis program (ImageJ™ 1 .42q, NIH, Bethesda, MD).
Detection of anti-LG3 antibodies (apoptotic bodies and nanovesicles experiments). Murine anti-LG3 antibodies were detected by ELISA using recombinant LG3 as the antigen. Sera were diluted (1/100) to perform the assay. Specific antibodies to LG3 were detected with anti-mouse IgG antibody coupled with horseradish peroxidase (HRP), followed by revelation
tetramethylbenzidine substrate which was stopped with sulfuric acid. Spectrophotometric analysis was performed at 450nm and titers are expressed as optical density (OD).
Cell culture and conditioned medium preparation. Murine EC (mEC) were isolated from the aorta of C57BI/6 mice, and grown in Dulbecco's Modified Eagle Medium (DMEM), low glucose culture media supplemented with endothelial cell growth supplements (ECGS), 10% FBS, 10% calf serum, 1 % penicillin-streptomycin and 1 % fungizone. To generate conditioned medium, cells were exposed to serum free medium for 8H. For all experiments, equal volumes of media conditioned by an equal number of cells were compared. We demonstrated in previous work that this system leads to the release of active mediators by apoptotic endothelial cells downstream of caspase-3 activation without cell membrane permeabilisation (Sirois I. et al. Cell Death Differ. 201 1 ; 18(3):p. 549-62).
Injection of murine apoptotic endothelial membrane vesicles. Transplanted mice received tail vein (150 μΙ_) IV injections of resuspended isolated vesicles. Each group received injections every other day during three weeks post-transplantation for a total of 8 doses.
Statistical analyses. When distributed normally, continuous variables are presented as means and standard deviations, otherwise as medians and interquartile ranges. Categorical variables are summarized as proportions. Between-group differences in categorical variables were assessed by chi-square tests (or Fisher's exact tests when expected frequencies were too small). Student's T tests were applied for continuous variables when the data was distributed normally. If such was not the case, Wilcoxon rank-sum tests were used. Associations between non-normally distributed continuous variables were analyzed by Spearman's correlation coefficients.
Example 2: Anti-LG3 antibodies increase obliterative remodeling in a murine model of vascular rejection
A murine model of pure vascular rejection, based on orthotopic transplantation of a fully MHC-mismatched aortic segment, was used to determine whether anti-LG3 behaves as an accelerator of allograft vascular injury. Transplantation of a fully MHC-mismatched aortic segment in absence of immunosuppression leads to subacute vascular inflammation and myointimal thickening progressing over 9 weeks (Soulez M, et al. Circ Res;110:94-104, 2012) Clamping the aortic allograft for 15 minutes before transplantation, aiming at reproducing the ischemic microenvironment sustained by organs from deceased donors, did not enhance vascular remodeling or leukocyte infiltration whereas prolonged ischemia for 30 minutes before transplantation, significantly increased neointima formation and allograft inflammation (FIGs. 3A and B, p=0.02). Vascular inflammation and neointima formation were specific to the allogeneic aorta, as the native aorta adjacent to the allograft did not show leukocyte infiltration or neointima formation (FIG. 4). Although largely described as a model of T-cell induced vascular injury,
allografted mice also showed increasing donor-specific antibody (DSA) titers within the first 3 weeks post-transplantation (FIGs. 3C and D, p<0.01).
To evaluate the impact of anti-LG3 on the development of vascular rejection, murine anti-LG3 IgGs or control IgGs were passively transferred to recipients of an allogeneic aortic graft exposed, or not, to 15 minutes of ischemia prior to transplantation. Fifteen minutes of ischemic preconditioning was chosen as this condition does not induce vascular remodeling or inflammation per se. Purified anti-LG3 or control IgG were passively transferred intravenously to aortic allograft recipients every other day for three weeks post-transplantation. Anti-LG3 IgG titers (predominantly lgG1 and lgG2b, FIG. 6) were significantly higher in mice transferred with anti-LG3 antibodies as compared with mice transferred with mouse IgG (FIG. 5A, p<0.01). DSA titers were similar in both groups (FIG. 5B). Amongst the 6 recipients of a non-ischemic aortic allograft passively transferred with anti-LG3 antibodies, 5 showed evidence of early neointima formation 3 weeks after transplantation, whereas only 1 of the 6 mice transferred with control IgG developed neointima (FIGs. 5C and D). There was a trend for increased intima-media ratios in mice passively transferred with anti-LG3 antibodies but this did not reach statistical significance (FIG. 5C, p=0.17). Infiltration of the allograft by mononuclear cells was not noticeably increased by anti-LG3 injection (FIG. 5D).
In recipients of an ischemic allograft, anti-LG3 transfer led to a considerable increase in mononuclear cell infiltration, including CD3 T cells and NK cells (FIGs. 7A and B, p=0.03 and 0.003 respectively). Massive and transmural allograft C4d deposition was also observed and was specific to the allogeneic vasculature as C4d deposition was not enhanced in the adjacent isogenic aorta (FIGs. 7A and 8). Intima-media ratios were also significantly increased in recipients of an ischemic allograft transferred with anti-LG3 IgG (FIG. 7a, p=0.04, FIG. 9).
It was next assessed whether an acute ischemic insult was sufficient for anti-LG3- induced complement activation and vascular remodeling or whether both the initial ischemic insult and ongoing immune-mediated vascular injury were involved. To this end, anti-LG3 antibodies were passively transferred to recipients of an ischemic isograft. There was a trend towards increased neointima formation in recipients of an isograft transferred with anti-LG3 antibodies but this did not reach statistical significance and C4d deposition was not noticeably increased (FIG. 9). Collectively, these results demonstrate that anti-LG3 antibodies significantly increase vascular inflammation and obliterative remodeling in allografts exposed to an initial ischemic insult followed by ongoing immune-mediated vascular injury.
Example 3: Apoptotic bodies inhibit the production of anti-LG3 antibodies and neointima formation that is triggered by the injection of apoptotic membrane nanovesicles
LG3 is released by apoptotic EC through caspase-3-dependent pathways and murine caspase-3 -/- EC release significantly less LG3 when exposed to a pro-apoptotic stimulus as
compared to wild-type EC (FIG. 10A). A novel type of membrane vesicles produced by apoptotic EC downstream of caspase-3 has been recently characterized (Sirois, I., et al., Cell Death Differ, 201 1. 18(3): p. 549-62). These membrane vesicles are functionally, structurally and biochemically distinct from classic apoptotic bodies and share common ultrastructural and biochemical markers with exosomes (FIG. 10B). Apoptotic bodies stem from blebbing of the cell membrane and their diameter ranges from 50 to 500 nm. Exosomes are secreted through fusion of multivesicular bodies with the cell membrane, range in size from 30 to 100 nm and present with a cup-shape morphology when evaluated by electron microscopy. (Sirois, I., et al., 201 1 , supra; Pallet, N., et al., Am J Transplant, 2012. 12(6): p. 1378-84; Thery, C, et al., Nat Rev Immunol, 2009. 9(8): p. 581-93). FIG. 10B shows membrane nanovesicles derived from apoptotic endothelial cells that share similarities with exosomes, such as size and morphology. To further characterize the distinct protein composition of apoptotic nanovesicles from apoptotic bodies, an unbiased proteomic screen was performed where the proteomes of endothelial apoptotic bodies and apoptotic nanovesicles was compared. LG3 was identified within both apoptotic bodies and apoptotic nanovesicles produced by serum starved apoptotic EC (FIG. 10C). Confocal microscopy confirmed the presence of LG3 within membrane vesicles released by apoptotic EC (FIG. 10D). As membrane vesicles are regulators of immune functions (Pallet, N., et al., 2012, supra; Thery, C, et al., 2009, supra), the possibility that membrane vesicles produced by apoptotic EC could prompt the production of anti-LG3 antibodies was considered. To test this hypothesis, mice transplanted with an allogeneic aortic graft were injected intravenously with either vehicle, apoptotic nanovesicles alone, apoptotic bodies alone, or medium containing both apoptotic bodies and membrane nanovesicles. In this murine model of aortic vascular rejection, mice injected with recipient membrane nanovesicles from endothelial apoptotic cells showed significant increases in anti-LG3 titers (p=0.001) and early neointima formation (p=0.01) compared to injections of vehicle (FIGs. 1 1A and B). Injections of a combination of nanovesicles and apoptotic bodies lead to decreased anti-LG3 titers (p=0.0003) and neointima formation (p=0.03) compared to the injection of nanovesicles alone (FIGs. 1 1A and B). Furthermore, infiltration of macrophages (F4/80) (FIG. 12A, p<0.05) and NK cells (Asialo) (FIG. 12B, p<0.05) was significantly increased in the aortic allograft recipients injected with apoptotic nanovesicles. Co-injection of apoptotic bodies and apoptotic nanovesicles blocked macrophage (FIG. 12A, p<0.05) and NK cell infiltration (FIG. 12B, p<0.05). These results provide evidence that LG3 is present in apoptotic nanovesicles from endothelial cells, is highly antigenic, and identify the release of apoptotic nanovesicles during endothelial death as a potential mechanism implicated in the production of anti-LG3 antibodies, neointima formation, and vascular injury and inflammation. Apoptotic bodies however tend to inhibit the production of anti-LG3 and vascular injury when mixed with apoptotic nanovesicles. This data provides evidence that apoptotic bodies, and more particularly apoptotic bodies derived from ECs, could
be used for developing novel methods of inhibiting the production of anti-LG3 antibodies and decrease the severity of vascular injury in transplant recipients experiencing acute vascular rejection. Although the present invention has been described hereinabove by way of specific embodiments thereof, the scope of the claims should not be limited by the preferred embodiments, but should be given the broadest interpretation consistent with the description as a whole and as defined in the appended claims. In the claims, the word "comprising" is used as an open-ended term, substantially equivalent to the phrase "including, but not limited to". The singular forms "a", "an" and "the" include corresponding plural references unless the context clearly dictates otherwise.
Claims
1. A method for preventing or decreasing vascular inflammation and/or obliterative remodeling in an allogeneic solid organ transplant recipient, said method comprising decreasing the level of, or neutralizing, anti-LG3 antibodies in said transplant recipient.
2. The method of claim 1 , wherein said method comprises decreasing the level of said anti- LG3 antibodies in said transplant recipient.
3. The method of claim 2, wherein said method comprises treating a biological sample comprising anti-LG3 antibodies from said transplant recipient to remove anti-LG3 antibodies from said sample, and reintroducing the biological sample into the transplant recipient.
4. The method of claim 3, wherein said treating comprises contacting the biological sample comprising anti-LG3 antibodies from said transplant recipient with a ligand that binds to said anti-LG3 antibodies, and removing the anti-LG3 antibody-ligand complexes from the biological sample.
5. The method of claim 4, wherein said ligand is an antibody.
6. The method of claim 5, wherein said antibody is an anti-human IgG antibody.
7. The method of claim 4, wherein said ligand is an LG3 polypeptide.
8. The method of claim 7, wherein said LG3 polypeptide comprises the sequence of SEQ ID NO:2 (FIG. 2C), or a sequence having at least 60% similarity or identity with the sequence of SEQ ID NO:2 (FIG. 2C).
9. The method of claim 8, wherein said LG3 polypeptide comprises the sequence of SEQ ID NO:2 (FIG. 2C), or a sequence having at least 80% similarity or identity with the sequence of SEQ ID NO:2 (FIG. 2C).
10. The method of claim 9, wherein said LG3 polypeptide comprises the sequence of SEQ ID NO:2 (FIG. 2C).
1 1. The method of any one of claims 4 to 10, wherein said ligand is bound onto a solid support.
12. The method of claim 11 , wherein said solid support is a chromatography resin or matrix.
13. The method of claim 1 1 or 12, wherein said solid support is in a chromatography column.
14. The method of any one of claims 3 to 13, wherein said biological sample is a blood- derived sample.
15. The method of any one of claims 2 to 14, wherein said method is performed during plasmapheresis of said transplant recipient.
16. The method of claim 2, wherein said method comprises administering to said transplant recipient an effective amount of autologous apoptotic bodies.
17. The method of claim 16, wherein said apoptotic bodies derive from endothelial cells.
18. The method of claim 1 , wherein said method comprises neutralizing the anti-LG3 antibodies in said transplant recipient.
19. The method of claim 18, wherein said method comprises administering to said transplant recipient an effective amount of an agent that binds to said anti-LG3 antibodies and inhibits their interaction with LG3.
20. The method of claim 19, wherein said agent is an antibody.
21. The method of any one of claims 1 to 20, wherein said method is performed prior to the transplantation.
22. The method of any one of claims 1 to 21 , wherein said method is performed after the transplantation.
23. The method of any one of claims 1 to 22, wherein the allogeneic solid organ transplant is from a deceased donor.
24. The method of any one of claims 1 to 23, wherein the solid organ is a kidney.
25. The method of any one of claims 1 to 24, wherein said method prevents acute vascular rejection in said subject.
26. Use of an agent that neutralizes anti-LG3 antibodies for preventing or decreasing vascular inflammation and/or obliterative remodeling in an allogeneic solid organ transplant recipient.
27. Use of an agent that neutralizes anti-LG3 antibodies for the preparation of a medicament for preventing or decreasing vascular inflammation and/or obliterative remodeling in an allogeneic solid organ transplant recipient.
28. The use of claim 26 or 27, wherein said agent is a ligand that binds to said anti-LG3 antibodies and inhibits their interaction with LG3.
29. The use of claim 28, wherein said agent is an antibody.
30. A kit for preventing or decreasing vascular inflammation and/or obliterative remodeling in an allogeneic solid organ transplant recipient, said kit comprising a ligand that binds to anti-LG3 antibodies bound to a solid support.
31. The kit of claim 30, wherein said solid support is a chromatography resin or matrix.
32. The kit of claim 30 or 31 , wherein said kit further comprises a chromatography column.
33. Use of the kit of any one of claims 30 to 32 for preventing or decreasing vascular inflammation and/or obliterative remodeling in an allogeneic solid organ transplant recipient.
34. An apheresis or plasmapheresis device comprising a chromatography column, said column comprising a ligand that binds to anti-LG3 antibodies bound to a solid support.
35. Use of autologous apoptotic bodies for preventing or decreasing vascular inflammation and/or obliterative remodeling in an allogeneic solid organ transplant recipient.
36. Use of autologous apoptotic bodies for the preparation of a medicament for preventing or decreasing vascular inflammation and/or obliterative remodeling in an allogeneic solid organ transplant recipient.
37. The use of claim 35 or 36, wherein said apoptotic bodies are derived from endothelial cells.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261729476P | 2012-11-23 | 2012-11-23 | |
US61/729,476 | 2012-11-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2014078963A1 true WO2014078963A1 (en) | 2014-05-30 |
Family
ID=50775356
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CA2013/050891 WO2014078963A1 (en) | 2012-11-23 | 2013-11-22 | Anti-lg3 antibody inhibition in the prevention and/or treatment of vascular rejection and related diseases and conditions |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2014078963A1 (en) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011109909A1 (en) * | 2010-03-08 | 2011-09-15 | Centre Hospitalier De L'université De Montréal | Anti-lg3 antibodies and uses thereof |
-
2013
- 2013-11-22 WO PCT/CA2013/050891 patent/WO2014078963A1/en active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011109909A1 (en) * | 2010-03-08 | 2011-09-15 | Centre Hospitalier De L'université De Montréal | Anti-lg3 antibodies and uses thereof |
Non-Patent Citations (3)
Title |
---|
CARDINAL, H. ET AL.: "Antiperlecan antibodies are novel accelerators of immune-mediated vascular injury.", AMERICAN JOURNAL OF TRANSPLANTATION, vol. 13, 22 February 2013 (2013-02-22), pages 861 - 874 * |
DIEUDE, M. ET AL.: "The LG3 perlecan fragment released by apoptotic endothelial cells accelerates vascular rejection.", XXIII INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY, 15 August 2010 (2010-08-15), Retrieved from the Internet <URL:http://www.tts.org/index.php?option=com_tts&view=presentation&id=1629> [retrieved on 20140113] * |
SOULEZ, M. ET AL.: "The Perlecan Fragment LG3 Is a Novel Regulator of Obliterative Remodeling Associated With Allograft Vascular Rejection.", CIRCULATION RESEARCH, vol. 110, 6 January 2012 (2012-01-06), pages 94 - 104 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Leventha et al. | Removal of baboon and human antiporcine IgG and IgM natural antibodies by immunoadsorption: results of in vitro and in vivo studies | |
Hall et al. | The cellular basis of allograft rejection in vivo. I. The cellular requirements for first-set rejection of heart grafts. | |
Jamin et al. | Autoantibodies against podocytic UCHL1 are associated with idiopathic nephrotic syndrome relapses and induce proteinuria in mice | |
Rose | Role of anti-vimentin antibodies in allograft rejection | |
Dantal et al. | Antihuman immunoglobulin affinity immunoadsorption strongly decreases proteinuria in patients with relapsing nephrotic syndrome. | |
CA2563408C (en) | Annexin v for preventing atherothrombois and plaque rupture | |
McLeod | Therapeutic apheresis: history, clinical application, and lingering uncertainties. | |
US10040859B2 (en) | Methods of treating hemophagocytic lymphohistiocytosis with an IL-33 receptor antibody | |
Pape et al. | Characterization of Cytolytic Effector Cells in Peripheral Blood of Healthy Individuals and Cancer Patients: I. Surface Markers and K Cell Activity After Separation of B Cells and Lymphocytes with Fc-Receptors by Column Fractionation | |
IL251210B1 (en) | Anti-age antibodies for treating inflammation and auto-immune disorders | |
JP6055464B2 (en) | Reduction of circulating soluble urokinase receptor | |
Anglicheau et al. | Posttransplant prophylactic intravenous immunoglobulin in kidney transplant patients at high immunological risk: A pilot study | |
Kwun et al. | The role of B cells in solid organ transplantation | |
Torres-Ruiz et al. | A potential role of neutrophil extracellular traps (NETs) in kidney acute antibody mediated rejection | |
Salvadori et al. | Current protocols and outcomes of ABO-incompatible kidney transplantation | |
Malvezzi et al. | Switching renal transplant recipients to belatacept therapy: results of a real-life gradual conversion protocol | |
Apaydin | The treatment of ANCA-associated rapidly-progressive glomerulonephritis and Goodpasture syndrome with therapeutic apheresis | |
Koenig et al. | B cells and antibodies in transplantation | |
Salvadori et al. | Impact of donor-specific antibodies on the outcomes of kidney graft: Pathophysiology, clinical, therapy | |
WO2017212391A1 (en) | An anti-c5 antibody dosing regimen | |
Vadivel et al. | Chronic allograft nephropathy | |
US6030614A (en) | Ameliorating immunological rejection of allograft | |
WO2014078963A1 (en) | Anti-lg3 antibody inhibition in the prevention and/or treatment of vascular rejection and related diseases and conditions | |
Rose | Role of antibodies in transplant-associated cardiac allograft vasculopathy | |
EP3548896B1 (en) | Use of anti-uchl1 igg plasma concentration for diagnosing idiopathic steroid sensitive nephrotic syndrome |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13856576 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 13856576 Country of ref document: EP Kind code of ref document: A1 |